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Chapter	I	
	
INTRODUCTION6	
	
Malaria	Burden		
Malaria	is	preventable	and	curable,	yet	it	remains	one	of	the	world’s	deadliest	diseases	due	to	increased	drug	resistance	and	minimal	resources.		Approximately	half	of	the	world’s	population	is	at	risk	for	contracting	malaria,	especially	young	children	and	pregnant	women	in	sub-Saharan	Africa.7	Additionally,	there	is	a	strong	correlation	between	malaria	endemic	regions	and	world	poverty.		A	vast	majority	of	malaria	victims	live	in	the	poorest	regions	of	the	world,	where	the	cost	of	prevention	and	treatment	can	consume	approximately	30%	of	a	family’s	income.8	The	protozoan,	Plasmodium	falciparum,	is	the	primary	causative	agent	of	this	infectious	disease	in	humans,	which	resulted	in	~214	million	cases	and	~438,000	deaths	in	2015.7	Four	additional	species	of	Plasmodium	are	known	to	infect	humans	(P.	vivax,	P.	malariae,	P.	ovale,	and	P.	knowlesi),	but	little	is	known	about	their	global	burden	still.9	While	this	disease	has	been	eradicated	from	the	United	States,	it	still	remains	a	major	public	health	concern	throughout	more	tropical	regions	of	the	world.		
In	the	past	decade,	there	has	been	a	reenergized	effort	to	develop	antimalarial	treatments.		These	include	strategies	to	replenish	the	drug	pipeline	
		 2	
with	new	small	molecule	therapeutics,	develop	combination	drug	therapies	against	resistance,	and	foster	an	effective	vaccine.	These	efforts	have	been	largely	driven	by	new	public	private	partnerships	such	as	Medicines	for	Malaria	Venture	(MMV),	the	Roll	Back	Malaria	Campaign,	the	President’s	Global	Health	Initiative,	and	the	Bill	and	Melinda	Gates	Foundation.		These	public	private	partnerships	have	registered	a	number	of	new	antimalarials	based	on	combination	therapies	of	older	mainline	treatments	(e.g.	Eurartesim,	Pyramax).10	Given	the	relative	maturity	of	the	malaria	drug	portfolio,	there	has	been	a	shortage	of	new	chemical	entities	entering	the	antimalarial	drug	pipeline.	There	are,	however,	signs	that	new	collaborative	approaches	to	discovery	may	soon	pay	significant	dividends.		
	
Parasite	Life	Cycle	
The	malaria	parasite	is	transmitted	between	hosts	through	the	bite	of	a	female	Anopheles	mosquito.7	Following	a	blood	meal	by	an	infected	mosquito	(Figure	1a),	sporozoites	are	deposited	from	their	salivary	glands	into	the	host	blood	stream	before	invading	hepatocytes	(Figure	1b).11	Here,	the	parasite	develops	into	hepatic	schizonts	and	eventually	merozoites,	which	are	released	back	into	the	bloodstream	(Figure	1c),	initiating	the	intraerythrocytic	stage	(Figure	1d).12	It	is	during	this	stage	of	infection	that	host	erythrocytes	are	destroyed	and	parasitic	toxic	waste	is	discharged,	causing	the	characteristic	symptoms	of	fever	and	chills	in	victims.		Once	a	merozoite	enters	the	red	blood	cell	it	grows	into	a	ring	form,	continues	to	mature	to	a	trophozoite,	and	finally	differentiates	into	an	erythrocytic	
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schizont	before	the	red	blood	cell	ruptures.		For	each	originally	infected	erythrocyte,	approximately	20	new	merozoites	are	then	expelled	into	the	bloodstream	and	remain	there	until	they	encounter	another	erythrocyte	to	invade,	allowing	infection	to	continue.13	Throughout	this	process,	a	few	of	the	merozoites	instead	enter	into	the	sexual	parasite	stage	through	which	gametocytes	are	formed	(Figure	1e).		The	gametocytes	continue	to	circulate	within	the	bloodstream	until	some	are	taken	up	by	a	mosquito	blood	meal	(Figure	1f)	and	can	then	undergo	fertilization	and	maturation	within	this	intermediate	host	before	being	transmitted	to	another	human	host	(Figure	1g).		A	majority	of	the	antimalarials	currently	on	the	market	inhibit	the	parasite	specifically	in	the	intraerythrocytic	stage.12	However,	if	malaria	is	to	be	completely	eradicated,	novel	drugs	must	be	developed	that	target	all	three	(hepatic,	erythrocytic,	and	gametocytic)	stages.		
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a 
b 
c 
d 
e 
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g 
Figure	1	The	life	cycle	of	Plasmodium	spp.	involves	two	different	hosts.		A	previously	infected		emale	Anopheles	mosquito	transmits	the	Plasmodium	parasite	into	the	bloodstream	of	the	human	host.	Within	this	host,	the	parasite	matures	and	rapidly	increases	in	number,	causing	physical	symptoms.	Some	parasites	differentiate	into	gametocytes,	which	can	then	be	taken	up	by	the	mosquito	host	and	subsequently	transmitted	to	other	humans	to	complete	the	life	cycle.5	
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Heme	Detoxification	Pathway	
During	the	trophozoite	stage	of	the	intraerythrocytic	life	cycle,	P.	falciparum	ingests	up	to	80%	of	the	host	hemoglobin	through	a	protozoan,	phagocytic	organelle	known	as	the	cytostome14	(Figure	2).6	The	cytostome	then	transports	hemoglobin	into	an	acidic	digestive	vacuole,	where	it	is	broken	down	by	proteolytic	enzymes	in	an	ordered	catabolic	process	into	small	peptides	to	be	used	as	nutrients	by	the	parasite.15	Consequently,	for	every	molecule	of	hemoglobin	that	is	consumed,	four	molecules	of	heme	(ferroprotoporphyrin	IX,	[Fe(II)PPIX])	are	released	and	oxidized	to	hematin	(ferriprotoporphyrin	IX,	[Fe(III)PPIX]).	Due	to	the	high	toxicity	of	free	heme,	organisms	must	rapidly	convert	this	molecule	into	an	inert	form,	many	through	the	enzyme	heme	oxygenase.16,	17	Most	hematophagous	organisms,	such	as	the	Plasmodium,	Schistosoma,	and	Boophilus	species,	lack	any	functional	heme	oxygenase	activity.17	Instead,	they	must	utilize	a	unique	pathway	to	crystalize	Fe(III)PPIX	into	a	non-toxic	biomineral,	known	as	hemozoin.17	Similar	to	the	tight	regulation	of	intracellular	heme	levels	in	vertebrates,	these	parasites	are	not	able	to	tolerate	high	levels	of	free	heme	without	harmful	effects.18	Thus,	it	is	likely	that	both	the	catabolism	and	crystallization	of	hematin	must	occur	at	comparable	rates	to	rid	the	cell	from	any	harm.		Egan	et	al.	found	the	kinetics	for	the	conversion	of	heme	to	hemozoin	to	be	so	fast	that	the	fraction	of	toxic	Fe(III)PPIX	would	never	exceed	1%	of	the	total	heme	found	in	the	parasite,	even	if	hemoglobin	degradation	occurred	at	a	constant	rate.19	
	
		 6	
	
Figure	2	Proposed	representation	of	hemozoin	formation	within	the	intraerythrocytic	life	cycle	of	Plasmodium	
falciparum.	Host	hemoglobin	is	taken	up	by	the	parasite	and	transported	to	the	digestive	vacuole	through	the	cytostome.	In	the	acidic	digestive	vacuole,	one	hemoglobin	protein	is	catabolized	into	small	peptides	and	four	toxic	heme	units.	Neutral	lipid	bodies	mediate	the	detoxification	of	free	heme	through	the	formation	of	an	inert	crystal,	hemozoin.	6		
Hemozoin	is	a	biologically	unique	dimer	of	five	coordinate	Fe(III)PPIX	linked	by	reciprocating	monodentate	carboxylate-linkages	from	one	of	the	protoporphyrin	IX’s	propionate	moieties.	The	biomineral	is	composed	of	an	extended	network	of	these	dimeric	units	hydrogen	bonded	together	via	the	second	propionic	acid	group	of	protoporphyrin	IX	(Figure	3).	More	recently,	the	crystal	structure	of	purified	
Plasmodium	hemozoin	was	solved	using	powder	X-ray	diffraction,	revealing	that	these	cross-linked	dimers	form	a	network	of	sheets	with	11.0Å	thickness.20	The	sheets	are	held	together	through	π-π	interactions,	causing	iron	atoms	to	be	partially	exposed	to	the	solvent,	which	allows	for	small	molecule	and	ligand	interaction	with	the	metal.		The	formation	of	such	an	insoluble	biomineral	sequesters	the	bulk	of	the	
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reactive	iron,	preventing	any	deleterious	reactions.		Disruption	of	this	process	has	been	shown	to	be	a	prime	target	for	antimalarial	drugs	because	hemozoin	is	unique	to	the	parasite,	but	more	importantly	because	this	is	a	non-enzymatic	pathway	and	therefore,	the	parasite	is	unable	to	develop	resistance	against	this	required	crystallization	process.15			
	
	
Figure	3	Schematic	illustration	of	the	structure	of	the	hemozoin	crystal	from	ferriprotoporphyrin	IX	dimers.	
	
For	the	past	20	years,	investigators	have	pondered	the	mechanism	of	formation	of	the	unique	heme	crystallite,	hemozoin.		Theories	include	enzyme	catalyzed	heme	polymerases,21	proteins	(specifically	histidine-rich	protein	and	heme	detoxification	protein),22,	23	and	lipid	mediation,24	or	a	combination	of	these.25	However,	the	most	recent	data	suggests	that	neutral	lipids	are	sufficient	to	effectively	mediate	the	formation	of	hemozoin.		One	piece	of	evidence	to	support	
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this	finding	is	the	discovery	of	neutral	lipids	present	in	the	digestive	vacuoles	of	early	trophozoite	stage	parasites.26	Since	Plasmodium	species	are	not	able	to	oxidize	these	lipids	for	energy,	they	must	have	an	alternative	function.27	Analysis	of	transmission	electron	micrographs	showed	these	lipid	nanospheres	surrounding	hemozoin	crystals,	providing	strong	evidence	that	hemozoin	formation	is	a	lipid-mediated	process.26	Through	electrospray	ionization	tandem	mass	spectrometry	the	composition	of	the	lipid	nanospheres	was	identified	as	a	blend	of	mono-	and	diglycerols:	monostearic,	monopalmitic,	dipalmitic,	dioleic,	and	dilinoleic	glycerol	in	a	specific	4:2:1:1:1	ratio.26	In	the	presence	of	the	lipid	blend	under	physiological	relevant	conditions,	β-hematin	(abiological	hemozoin)	formation	was	found	to	have	a	half-life	of	approximately	two	minutes.28	The	in	vitro	kinetics	of	β-hematin	formation	mediated	by	neutral	lipids	is	kinetically	competent	to	handle	the	necessary	flux	of	monomeric	Fe(III)PPIX	to	prevent	it	from	reaching	toxic	levels	physiologically.		While	heme	begins	to	localize	and	accumulate	within	this	parasitic	organelle,	the	acidic	environment	containing	neutral	lipid	droplets	(NLDs)	allows	for	the	rapid	detoxification	of	this	lethal	molecule.		The	requirement	for	lipids	in	this	process	is	exemplified	through	favored	formation	of	the	iron	(III)-carboxylate	bond	in	a	hydrophobic	environment.29	Lipid	mediation	of	hemozoin	formation	was	also	found	to	be	more	efficient	than	autocatalysis,	as	the	digestive	vacuole	membrane	could	serve	as	a	scaffold	or	nucleation	site	for	the	growing	crystal.30	Furthermore,	Kapishnikov	et	al.	observed	crystals	lying	on	their	long	axis	along	the	digestive	vacuole	membrane,	an	unlikely	orientation	unless	the	lipid	membrane	was	involved	in	crystal	growth	nucleation.31	These	results	not	only	provide	the	criteria	for	lipid-
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mediated	formation	of	hemozoin,	but	also	critical	information	for	the	development	of	approaches	to	prevent	this	detoxification	from	occurring,	which	has	been	an	effective	drug	target	for	malaria	treatment.		
	
	 	 Current	Antimalarial	Drugs	
In	the	1600s,	an	extract	of	the	cinchona	bark,	quinine,	was	found	to	have	antimalarial	properties.32	In	addition,	qinghaosu	(from	the	Chinese	plant	Artemisia	
annua)33	was	isolated	after	observing	its	antimalarial	healing	properties.		These	two	natural	product	extracts	have	inspired	many	of	the	antimalarials	on	the	market	today.		Current	antimalarial	drugs	can	be	divided	into	four	classes	based	on	chemotype	and	mechanism	of	action	(Table	1).	
Chloroquine	(CQ),	once	the	most	successful	antimalarials,	is	a	4-aminoquinoline	known	to	inhibit	the	hemozoin	detoxification	pathway.		Following	treatment,	this	chemotype	is	evenly	distributed	throughout	the	parasite	cytoplasm,	but	due	to	its	weak	base	properties,	it	accumulates	within	the	acidic	digestive	vacuole	(pH	4.8-5.2)	through	an	ion	trapping	mechanism.34	Upon	entering	the	acidic	environment,	CQ	is	doubly	protonated	and	becomes	membrane	impermeable,	causing	it	to	reach	millimolar	concentrations	compared	to	nanomolar	concentrations	in	the	plasma.35	This	property	allows	for	low	doses	of	CQ	to	be	administered	to	malaria	victims,	as	it	is	concentrated	in	the	biological	location	of	hemozoin	formation,	the	molecular	target.		The	parasite	begins	to	degrade	hemoglobin	in	the	early	stages	of	the	life	
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cycle	and	quickly	converts	the	toxic	heme	byproduct	into	hemozoin;	therefore,	hemozoin	inhibitors	are	effective	at	the	ring	stage	of	the	life	cycle.36			
	
Table	1	Four	classes	of	current	antimalarial	drugs	
Biological	pathway	 Chemical	class	 Example	antimalarial	
Hemozoin	formation	 Aminoquinolines	Arylamino	alcohols	 Chloroquine,	Mefloquine	
Folate	biosynthesis	 Sulfonamides	Biguanides	Aminopyrimidines	 Sulfadoxine,	Proguanil,	Pyrimethamine	Electron	transport	chain	 Naphthoquinones	 Atovaquone	
Unknown	target	 Artemisinin	derivatives	 Artesunate,	Artemether	
	
	 The	folate	biosynthesis	pathway	is	a	clinically	proven	target	with	drugs	designed	against	it	used	for	both	treatment	and	prophylaxis.37	Examples	of	these	include	sulfadoxine,	which	inhibits	dihydropteroate	synthase,	and	pyrimethamine	(PYR),	which	blocks	dihydrofolate	reductase	activity,	ultimately	affecting	the	production	of	purines	and	pyrimidines	used	in	DNA	replication.		Since	DNA	synthesis	is	more	prevalent	at	the	trophozoite	stage,	this	class	of	compounds	targets	the	later	part	of	the	48-hour	life	cycle.38		
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	 Atovaquone	(ATV),	a	hydroxynaphthoquinone,	is	known	to	inhibit	the	bc1	complex	of	the	parasite	mitochondrial	electron	transport	chain.39	When	mitochondrial	function	decreases,	the	parasite	is	no	longer	able	to	produce	orotate,	a	precursor	for	pyrimidine	biosynthesis.	The	greatest	amount	of	DNA	replication	occurs	during	the	trophozoite	stage	of	the	life	cycle,	thus	ATV	is	most	effective	as	the	parasite	is	preparing	for	division.		There	is	little	effect	seen	on	the	merozoite	and	ring	stages	since	here,	DNA	replication	is	minimal.40		
In	the	1970s,	artemisinin	(ART)	was	isolated	as	an	effective	antimalarial	natural	product	with	artemisinin	combination	therapy	currently	as	the	best	option	for	malaria	treatment.41	While	the	exact	mechanism	of	action	of	the	ART	family	of	compounds	is	highly	debated,	it	is	generally	agreed	that	the	endoperoxide	bridge	of	ART	and	its	derivatives	is	activated	by	iron,	causing	free	radicals	to	form	inside	the	parasite.42	The	free	radicals	can	then	continue	to	alkylate	heme	and	various	proteins,	inducing	parasite	death	either	by	creating	redox-active	heme	adducts43	or	by	damaging	DNA	and	disrupting	cell	division.44	Further	evidence	of	this	was	observed	through	the	addition	of	free	radical	scavengers	and	iron	chelators,	which	resulted	in	antagonistic	properties.42	The	endoperoxide	moiety	is	essential	for	biological	activity,	as	derivatives	of	ART	without	this	bridge	do	not	possess	antimalarial	activity.45		
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Widespread	Antimalarial	Resistance	
	 The	malaria	parasite	is	ever	evolving	and	thus,	with	delayed	parasite	clearance	in	hosts,	resistance	to	antimalarial	drugs	is	observed.		Parasite	resistance	is	found	in	three	of	the	five	human	Plasmodium	species	(P.	falciparum,	P.	vivax,	and	
P.	malariae).46	Typically	it	originates	near	the	Thailand-Cambodia	border	and	migrates	through	the	remaining	malaria	endemic	countries	in	Southeast	Asia	and	sub-Saharan	Africa,	until	now	all	95	countries	with	ongoing	malaria	transmission	have	parasites	resistant	to	CQ	and	sulfadoxine-PYR.47			
While	artemisinin	combination	therapies	are	currently	the	last	line	of	defense,	resistance	has	already	emerged	along	the	Thailand-Cambodia	border	and	continues	to	spread.48	However,	therapies	are	still	effective	as	a	drug	combination	approach	allows	for	effective	treatment	during	the	life	cycle	stages	at	which	ART	resistance	is	observed.		Therefore,	understanding	the	mechanism	of	action	for	all	antimalarial	compounds	will	help	improve	the	design	of	novel	compounds	in	ways	that	may	reduce	rapid	resistance	through	combination	therapy	with	two	distinct	biological	targets.		
In	the	1940s,	CQ	became	the	most	widely	used	antimalarial	drug	and	continued	to	be	effective	against	P.	falciparum,	at	least	in	part,	until	resistance	was	found	throughout	all	endemic	regions	in	1989.34	Despite	this	resistance	and	diminished	efficacy	of	quinine	and	its	derivatives,	hemozoin	remains	a	suitable	target	for	antimalarial	drugs.		Resistance	to	this	class	of	drugs	arises	from	mutations	or	changes	in	expression	levels	in	two	digestive	vacuole	membrane	proteins,	namely	
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the	CQ	resistant	transporter	protein	(PfCRT)49	and	a	homolog	of	P-glycoprotein	in	the	case	of	mefloquine.50	These	proteins	are	believed	to	reduce	drug	concentrations	in	the	digestive	vacuole,	as	PfCRT	appears	to	either	actively	or	passively	move	CQ	out	of	this	compartment.51,	52	The	cause	of	resistance	is	attributed	to	a	point	mutation	(K76T)	in	PfCRT,	causing	a	lack	of	the	positively	charged	lysine	residue	to	repel	the	charged	CQ	in	the	digestive	vacuole	cytosol,	allowing	it	to	be	efflux	pumped	out	of	the	digestive	vacuole.		The	putative	target	of	these	drugs	(Fe(III)PPIX)	arises	from	the	host	and	is	not	under	genetic	control	of	the	parasite,	rather	it	is	a	chemically	fixed	structure	and	is	invariantly	present	in	large	amounts	in	the	environment	in	which	the	parasite	lives.	Thus,	the	parasite	would	appear	to	have	little	choice	but	to	produce	hemozoin,	making	it	a	valid	drug	target,	and	impervious	to	resistance.	Consequently,	it	is	vital	to	understand	the	mechanism	of	hemozoin	inhibitors	to	establish	effective	antimalarial	compounds	against	this	biological	pathway.	
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Chapter	II	
	
DETERMINATION	OF	BIOLOGICAL	MODELS	FOR	HEMOZOIN	FORMATION4		
	
Introduction	
The	role	of	lipids	in	hemozoin	formation	
	 Although	the	mechanism	by	which	P.	falciparum	detoxifies	Fe(III)PPIX	into	hemozoin	is	not	agreed	upon,	one	hypothesis	has	indicated	a	role	for	NLDs	in	crystal	formation.	Transmission	electron	microscopy	(TEM)	revealed	hemozoin	crystals	associated	with	the	surface	of	lipid	droplets	and	are	found	within	the	digestive	vacuole	of	mature	trophozoites.53	Moreover,	synthetic	NLDs	composed	of	the	identical	parasite	blend	of	lipids	were	shown	to	promote	β-hematin	formation	at	a	physiological	rate	under	biological	conditions,	which	was	not	observed	under	purely	aqueous	conditions.54	This	suggests	that	hemozoin	formation	favors	a	lipophilic	environment,	and	more	specifically	prefers	growth	along	a	lipid/water	interface.		
	 An	alternative	model	of	hemozoin	formation	in	Plasmodium	spp.	involves	this	crystal	nucleating	on	the	inner	surface	of	the	digestive	vacuole	membrane	as	opposed	to	on	NLDs.31	Through	cryogenic	synchrotron	soft	x-ray	tomography,	hemozoin	crystals	were	found	oriented	with	the	polar	head	groups	exposed,	allowing	for	the	free	propionic	acid	groups	to	hydrogen	bond	and	continued	
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extension	along	the	curved	surface	near	the	lipid/water	interface.55,	56	Each	of	these	models	describing	hemozoin	formation	relies	on	heme	interacting	with	lipids;	therefore	to	investigate	this	mechanism	further,	we	focused	on	understanding	the	role	of	lipids	in	this	detoxification	process.			
	
High-throughput	β-hematin	inhibition	assays	
A	number	of	high-throughput	assays	have	previously	been	developed,	initially	using	antimalarials	with	well-determined	target	pathways,	to	test	for	in	
vitro	β-hematin	inhibition.	In	these	assays,	quinoline	derivatives	were	most	commonly	used	as	positive	controls	for	hemozoin	inhibition,	while	folate	biosynthesis	and/or	mitochondrial	inhibitors	were	chosen	as	negative	controls.57	β-hematin	has	been	shown	to	be	the	synthetic	analogue	to	hemozoin	chemically,	spectroscopically,	and	crystallographically	and	can	be	produced	in	the	laboratory	in	a	high-throughput	screening	format	under	conditions	mimicking	the	physiology	of	the	parasite.15	
	Originally,	assays	developed	to	screen	for	β-hematin	inhibition	relied	on	the	incorporation	of	radioactive	[14C]	hemin	into	the	growing	crystal,	followed	by	quantitation	using	a	scintillation	counter.58	While	this	is	a	simple	and	sensitive	assay,	it	is	expensive	and	requires	the	use	of	radioactive	materials.		Other	in	vitro	assays	were	later	developed	to	resolve	the	complications	of	working	with	radioactive	material	through	using	the	innate	absorption	properties	of	hematin	or	
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through	colorimetric	quantification.		While	these	methods	do	not	require	radiolabeled	hematin,	other	limitations	include	centrifugation	and	transfer	steps	and	lengthy	(≥	24	hour)	incubation	times,	which	decrease	the	throughput	of	the	assay.59	The	detergent,	Tween	20,	was	found	to	be	a	good	initiator	for	β-hematin	formation,	allowing	for	an	inexpensive,	simple,	and	quick	(four	hour	incubation)	assay	without	any	purification	or	transfer	steps.60	However,	the	β-hematin	50%	inhibitory	concentration	(IC50)	dose	response	values	of	known	antimalarials,	such	as	CQ,	were	ten-fold	greater	with	Tween	20	than	reported	with	the	specific	blend	of	physiological	neutral	lipids.60	The	increased	value	may	indicate	that	Tween	20	does	not	accurately	mimic	the	biological	nature	found	within	the	parasite	and	may	instead	initiate	hemozoin	formation	through	an	alternative	method.	
More	recently,	chemical	colorimetric	high-throughput	assays	have	been	developed	and	used	to	screen	compound	libraries.		Results	from	these	screens	were	subsequently	examined	for	parasite	efficacy,	which	the	previously	mentioned	assays	failed	to	test.		Due	to	differential	solubility	characteristics	of	heme	and	β-hematin	through	the	addition	of	pyridine,	the	amount	of	hemin	not	converted	into	crystal	form	can	be	quantified	spectrophotometrically.61	One	colorimetric	assay	was	developed	for	384-well	microtiter	plates,	which	incubated	a	hemin	solution	at	60°C	for	two	hours	before	quantifying	with	pyridine.62	While	rapid,	this	assay	did	not	effectively	recapitulate	the	biology	that	occurs	in	the	parasite	digestive	vacuole.		In	fact,	due	to	the	high	acetate	concentration,	the	mechanism	of	formation	for	β-hematin	in	this	assay	is	a	complex	phase-transfer	catalysis	mechanism	that	is	most	likely	not	occurring	in	the	parasite.		Consequently,	in	this	screen	644	pathway	hits	
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were	identified	as	β-hematin	inhibitors	from	their	pilot	screen	of	16,000	compounds,	but	only	17	(2.6%)	were	found	to	also	have	antiplasmodial	activity	against	P.	falciparum.		Carter	et	al.	established	a	high-throughput	in	vitro	detergent	based	assay	that	more	closely	represented	the	biological	conditions	in	which	hemozoin	formation	occurs.	This	method	eliminated	the	use	of	radioactive	materials	and	transfer	steps,	utilized	physiological	pH	and	temperature,	and	additionally	only	required	a	short	(six	hour)	incubation	time,	increasing	the	throughput	of	the	assay.		Not	only	did	the	positive	and	negative	controls	of	known	antimalarials	hold	true	using	the	Nonidet	P-40	(NP-40)	detergent,	but	also	testing	of	known	hemozoin	inhibitors,	CQ	(48.7	μM)	and	amodiaquine	(AQ)	(21.0	μM),	resulted	in	similar	dose	response	concentrations	to	the	values	reported	with	the	synthetic	NLDs	(85.3	and	23.1	μM,	respectively).63	This	detergent-mediated	assay	was	subsequently	used	in	a	pilot	screen	of	38,400	compounds	to	test	for	β-hematin	activity	(Figure	4).63	161	inhibitors	of	β-hematin	were	identified	from	this	screen	conducted	in	384-well	microtiter	plates,	which	correlated	to	a	0.42%	hit	rate	and	113	compounds	exhibiting	IC50	values	less	than	the	positive	control	drug,	AQ.		The	compounds	identified	as	β-hematin	inhibitors	were	then	screened	for	in	vitro	P.	falciparum	activity	and	48	compounds	(30%)	were	found	to	inhibit	more	than	90%	of	parasite	growth	in	a	CQ	sensitive	strain	(D6),	while	40	compounds	retained	activity	in	a	multidrug	resistant	strain	(C235).	The	fact	that	this	particular	screen	resulted	in	a	high	percentage	of	parasite	active	hits,	with	a	low	false-positive	hit	rate	(0.016%),	demonstrates	the	importance	for	development	of	an	assay	that	accurately	replicates	the	physiological	conditions	present	in	vivo.63	
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Figure	4	Workflow	of	the	high-throughput	β-hematin	assay	developed	by	Carter	et	al.	Test	compounds	were	acoustically	delivered	using	a	noncontact	liquid	handler,	followed	by	the	addition	of	buffer,	hemin,	and	detergent	(Nonidet	P-40).	The	384-well	plates	were	incubated	at	37°C	for	six	hours	before	the	addition	of	5%	(v/v)	pyridine.	The	absorbance	value	of	the	ferrichrome	complex	(405	nm)	was	compared	to	positive	and	negative	controls	to	establish	hits.2,	61,	63	
	
Systematic	investigation	of	detergents	to	understand	biological	environment	
Abiological	molecules,	such	as	phospholipids,	alcohols,	acids,	and	detergents	have	been	shown	to	mimic	the	effects	of	NLDs	in	hemozoin	formation.30,	61,	64,	65	Like	lipids,	detergents	are	amphiphilic	molecules	and	can	form	different	nanostructures	depending	on	pH,	temperature,	concentration,	and	the	presence	of	ions	in	the	experimental	environment.	With	no	detailed,	systematic	investigation	of	detergent-mediated	β-hematin	formation	previously	reported,	eleven	detergents	were	systematically	chosen	to	understand	the	physicochemical	properties	of	detergents	that	best	resemble	hemozoin	formation	in	vivo.		This	methodical	examination	will	
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help	explain	the	reasoning	behind	the	success	of	our	β-hematin	formation	in	vitro	screening	assay	compared	to	others	in	the	literature.60,	63	
	
	 	 Experimental	Methods	
Materials	
	 Triton	X	detergents	(45,	114,	100,	102,	165,	and	305),	Tween	20,	Tween	80,	dodecyl	sulfate	sodium	salt	(99%),	pyridine	(≥	99%),	amodiaquin	dihydrochloride	dihydrate,	sodium	acetate	trihydrate,	and	hemin	(≥	98%,	Fluka)	were	purchased	from	Sigma	Aldrich.	Flat	bottom,	384-well	clear	plates	(3680,	Corning)	and	3-[(3-cholamidopropyl)	dimethylammonio]-1-propanesulfonate	(Pierce)	were	purchased	from	Fisher	Scientific.	Nonidet	P-40	(Shell	Chemical	Co.)	was	purchased	from	Pierce	Biotechnology,	Rockford,	IL,	but	has	been	discontinued	and	should	not	be	mistaken	for	detergents	that	other	companies	refer	to	as	NP-40.		
	
Detergent	phase	transition	melting	temperatures		
	 Phase	transition	melting	temperatures	of	the	detergents	were	determined	by	differential	scanning	calorimetry	(DSC)	on	a	TA	Instruments	DSC	Q1000.		The	samples	consisted	of	pure	detergents	as	obtained	from	the	supplier	pressed	in	aluminum	standard	pans.	Each	sample	was	equilibrated	at	100°C	for	5	minutes	followed	by	three	cycles	of	scans	ranging	from	100°C	to	-100°C	at	10°C/minute	and	
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back	up	to	100°C	with	5	minute	isothermal	steps	at	each	end	of	the	cycle.		Melting	transitions	were	determined	from	heat-cool-heat	plots	showing	changes	in	heat	flow	with	respect	to	time	and	temperature	and	analyzed	using	Universal	V4.5A	TA	Instruments	software.			
	
Critical	micelle	concentration	of	detergents	
	 The	critical	micelle	concentration	(CMC)	of	each	detergent	under	assay	conditions	was	determined	using	an	Attension	Sigma700	Tensiometer.	The	concentrations	tested	ranged	from	5	µM	to	1	mM	for	all	detergents,	except	for	3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate	(CHAPS),	which	spanned	a	broader	range	of	5	µM	to	11	mM.		Stock	solutions	(2	mM)	of	each	detergent	were	prepared	in	a	1	M	acetate	buffer	(pH	4.8)	and	the	appropriate	volume	of	stock	was	added	to	a	50	mL	conical	tube	and	diluted	to	the	desired	concentration	with	additional	acetate	buffer.		Higher	concentration	solutions	for	CHAPS	were	prepared	by	weighing	out	the	appropriate	mass	into	50	mL	conical	tubes	and	diluting	with	acetate	buffer.		The	tubes	were	pre-incubated	in	a	37°C	water	bath	for	one	hour.		Sample	tubes	were	removed	from	the	bath	and	placed	in	a	temperature-controlled	environment	while	the	surface	tension	was	measured	using	a	Du	Noüy	ring.	CMCs	were	generated	using	segmented	linear	regression	fitting	methods	with	GraphPad	Prism	v5.0,	as	described	by	Provera	et	al.66	
Heme	solubilization	and	crystallization		
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The	effect	of	detergents	on	heme	solubility	was	determined	using	a	method	previously	described	by	Stiebler	et	al.65	Briefly,	hemin	chloride	in	1%	DMSO	(100	µM	final	concentration)	was	mixed	with	each	detergent	(10	mM)	in	1	M	sodium	acetate	buffer	(pH	4.8)	for	10	minutes.		Following	centrifugation	at	17,100	g	for	5	minutes,	the	supernatant	was	collected.		To	quantify	the	amount	of	free	heme	remaining	in	solution,	a	300-µL	aliquot	of	the	supernatant	was	added	to	700	µL	of	an	alkaline-pyridine	solution	(48%	pyridine,	200	mM	NaOH)	and	the	absorbance	was	measured	on	a	Synergy	H4	Hybrid	Plate	Reader	(BioTek)	between	300	–	700	nm.			
The	detergent	effect	on	heme	crystallization	was	calculated	following	formation	of	β-hematin	product	after	120	minutes,	the	average	half-life	of	all	detergents.	Briefly,	each	detergent	was	prepared	at	a	concentration	of	100	µM	in	acetate	buffer	(1	M,	pH	4.8)	and	added	to	1.5	mL	microcentrifuge	tubes.		The	tubes	were	pre-incubated	in	a	37°C	water	bath	for	15	minutes.		Hemin	chloride	was	first	dissolved	in	DMSO	to	make	a	25	mM	hematin	stock	solution.		A	100-µM	hematin	suspension	was	prepared	by	adding	the	stock	solution	to	1	M	acetate	buffer	(pH	4.8,	37°C).	An	equal	amount	of	the	hematin	suspension	was	added	to	the	warmed	detergents	to	make	a	final	mixture	of	50	µM	detergent	(the	lowest	concentration	at	which	maximum	β-hematin	formation	is	observed	for	all	detergents)	and	50	µM	hematin	in	1	M	acetate	buffer.	The	tubes	were	shaken	at	45	rpm	and	removed	after	120	minutes	for	free	heme	quantification	using	the	alkaline-pyridine	method.	The	average	amount	and	standard	deviation	(n	=	3)	of	heme	crystallized	into	β-hematin	
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during	this	time	frame	was	calculated	using	mass	balance	of	the	heme	starting	material	and	the	amount	of	free	heme	remaining	in	solution.		
	
Results	and	Discussion	
Our	lab’s	in	vitro	target-based	assay	utilizes	a	nonionic	detergent	as	a	NLD	mimic	to	mediate	β-hematin	formation.		The	high	resemblance	of	the	β-hematin	product	formation	of	NP-40	with	the	synthetic	NLDs	may	be	due	to	the	similarity	in	their	molecular	structure.		The	Triton	X	detergents	possess	a	polyethylene	oxide	(PEO)	hydrophilic	moiety	which	is	similar	to	the	glycerol	hydrophilic	portion	of	the	parasite	neutral	lipids.		Therefore	to	understand	structural	effects,	eleven	detergents	were	examined	for	their	effectiveness	as	a	lipophilic	mediator	for	β-hematin	formation.	Sodium	dodecyl	sulfate	(SDS)	and	CHAPS	were	chosen	as	ionic	and	zwitterionic	detergents,	respectively,	to	examine	the	effects	of	charge	on	β-hematin	formation.		Due	to	previous	literature	precedence,60	Tween	20	was	included	in	the	study	with	Tween	80	added	as	a	comparison.	Each	of	these	nonionic	detergents	has	the	same	PEO	hydrophilic	head	group,	but	differ	in	the	length	of	the	fatty	acid	ester	portion.	Tween	20	has	a	saturated	11	carbon	hydrophobic	tail	and	Tween	80	exhibited	a	single	point	of	unsaturation	in	its	17-carbon	tail.	The	Triton	X	series	of	detergents	were	chosen	to	systematically	evaluate	the	effects	of	hydrophilicity	on	β-hematin	formation	as	these	molecules	only	differ	in	the	length	of	PEO	tails.	Triton	X-45,	-114,	-100,	-102,	-165,	and	-305	have	an	average	of	4.5,	7.5,	9.5,	12,	16,	and	30	PEO	units,	respectively.		
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Detergent	phase	transition	melting	temperatures	
	 By	TEM,	morphological	differences	were	observed	for	β-hematin	crystals	formed	by	various	detergents	(Figure	5).	Product	variation	is	most	likely	affected	by	the	physical	state	of	the	detergents	based	on	environmental	conditions.	The	β-hematin	product	formed	by	SDS	resulted	in	fewer	well-formed	crystals	with	more	irregular	shapes	that	do	not	resemble	biological	hemozoin	(Figure	5C).	The	melting	temperature	of	SDS	was	found	to	be	206°C,	which	is	significantly	higher	than	the	experimental	conditions	used.67	This	would	cause	the	detergent	structures	to	have	increased	rigidity,	hindering	β-hematin	formation	due	to	decreased	accessibility	of	heme	into	the	detergent	lipophilic	core.			
	
Figure	5	The	external	morphology	of	product	obtained	from	incubation	of	heme	with	(A)	TX9.5	(B)	NP-40	at	pH	4.8	and	37⁰C	reveal	well-formed	crystals	that	resemble	biological	hemozoin.	Not	all	detergents	(C)	SDS	produced	well-structured	crystals.	Scale	bars	represent	500	nm.	Images	courtesy	of	Dr.	Christopher	P.	Gulka.4		
	 	
C A B 
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Alternatively,	the	Triton	X	series	of	detergents	formed	product	that	best	resemble	hemozoin	and	had	crystals	ranging	from	200	–	1000	nm	in	size	according	to	both	TEM	images	and	dynamic	light	scattering	(DLS).	These	nonionic	detergents	were	found	to	have	phase	transition	temperatures	around	or	below	the	experimental	temperature	used	(37°C),	allowing	some	fluidity	in	the	detergent	aggregates	and	β-hematin	to	form	(Figure	6).		The	deviation	of	SDS-mediated	β-hematin	from	the	behavior	observed	by	synthetic	NLDs	and	the	Triton	X	detergents	may	be	from	the	strong	interactions	between	its	polar	head	group	and	suggests	that	this	detergent	does	not	serve	as	a	valid	model	system	for	biological	NLDs.			
	
Characterization	of	detergent	structures	and	the	effect	on	β-hematin	formation	
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Figure	6	Phase	transition	melting	temperatures	determined	by	differential	scanning	calorimetry.	Melting	transition	temperatures	were	determined	following	three	cycles	of	heat-cool-heat	scans.		Longer	hydrophilic	chains	correlate	to	higher	melting	temperature	among	the	Triton	X	series	of	detergents.4		
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	 To	initiate	growth	of	the	β-hematin	crystal,	the	porphyrin	rings	of	two	Fe(III)PPIX	molecules	overlap	through	π-π	interactions	forming	columnar	aggregates	of	dimeric	units.		Extension	in	a	second	dimension	results	from	iron-propionate	linkages	between	dimers,	which	help	stabilize	the	crystal	structure	in	the	aqueous	digestive	vacuole.20	Formation	of	this	dimer	linkage	requires	displacement	of	axial	water	molecules	from	the	iron	center.		Using	molecular	dynamic	simulations,	Egan	and	coworkers	demonstrated	that	displacement	of	the	water	molecule	is	favored	under	lipophilic	conditions,	such	as	the	environment	offered	by	NLDs,	phospholipids,	and	detergents.19	Previous	studies	have	shown	that	several	detergents	promote	β-hematin	formation,	though	the	role	of	detergent	dynamics	was	not	studied.61	The	similarity	between	NLDs	and	detergent	nanostructures	resulted	in	a	hypothesis	that	the	optimal	detergent	concentration	for	β-hematin	formation	correlated	with	the	presence	of	a	similar	environment	of	structured	amphiphilicity	as	well	as	the	detergent	CMC.		
	 The	nonionic	detergent	structures	did	not	abide	by	the	true	definition	of	a	micelle	since	the	optimal	concentrations	for	β-hematin	formation	were	lower	than	the	CMCs	determined	under	assay	conditions	(37°C	and	pH	4.8).		However,	there	was	still	a	relationship	observed	between	detergent	hydrophilic	chain	length	and	CMC	(Figure	7).		It	is	hypothesized	that	the	detergents	formed	aggregates	instead	of	micelles	since	at	the	optimal	detergent	concentration	a	single,	albeit	broad,	peak	was	observed	by	DLS	under	identical	conditions.		This	supports	the	hypothesis	that	a	hydrophobic	environment	is	required	for	the	axial	water	ligand	to	be	released	
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from	the	iron	center	and	coordination	of	a	second	heme	molecule	to	occur.		The	amphiphilic	detergent	aggregates	still	allow	for	the	sequestering	and	solubilization	of	Fe(III)PPIX	to	form	β-hematin	crystals.		According	to	DLS	measurements,	the	size	distribution	of	the	detergent	aggregates	range	from	100	–	300	nm	and	are	in	agreement	with	TEM	images	obtained.		Since	micelles	are	typically	<	20	nm	in	diameter,	these	results	support	aggregate	formation	under	assay	conditions	with	structure	based	on	polarities.		Furthermore,	these	sizes	observed	are	consistent	with	that	previously	reported	for	synthetic	NLDs.54	
	
	
Detergent	effects	on	heme	solubilization	and	crystallization		
	 Concentrated	within	the	digestive	vacuole,	NLDs	are	thought	to	serve	as	a	reservoir	for	amphiphilic	heme	upon	release	from	hemoglobin.28	In	support	of	this	hypothesis,	β-hematin	is	unlikely	to	form	in	an	aqueous	medium	at	a	physiological	rate,	implying	that	a	lipid	environment	would	aid	in	the	solubilization	of	heme,	
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Figure	7	(A)	A	positive	relationship	is	observed	between	the	CMC	(average	of	three	replicates	and	standard	deviation)	for	the	Triton	X	series	of	detergents	and	the	average	length	of	the	hydrophilic	PEO	side	chain.	(B)	The	optimal	detergent	concentration	for	each	detergent	is	less	than	the	CMC	under	assay	conditions,	indicating	structured	micelles	are	not	required	for	β-hematin	formation.4	
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similar	to	the	ideal	environment	reported	with	phospholipid65	and	octanol68	mediated	β-hematin	formation.	The	effect	of	hydrophobicity	on	heme	solubilization	was	assessed	through	comparing	the	Triton	X	series	of	detergents.		A	10	mM	detergent	solution	in	acetate	buffer	(1	M,	pH	4.8)	was	incubated	with	100	µM	hematin	in	DMSO	for	10	minutes,	followed	by	quantification	of	solubilized	heme	by	the	alkaline-pyridine	method.69	An	incubation	time	of	less	than	the	half-life	of	β-hematin	formation	for	each	detergent	ensures	the	measurement	of	soluble	heme	alone	with	only	minimal	crystallization	present.	The	Triton	X	detergent	aggregates	solubilize	heme,	following	the	trend	of	TX30	>	TX16	>	TX12	>	TX9.5	>	NP-40	>	TX7.5	>	TX4.5.		Heme	is	then	sequestered	into	the	hydrophobic	core,	resulting	in	increased	heme	solubility	at	the	early	stages	of	crystallization	(Figure	8A).	This	is	consistent	with	previous	trends	found	with	PEO	containing	detergents	and	organic	solvents,	which	result	in	faster	β-hematin	formation	and	lower	optimal	detergent	concentrations	with	longer	chain	lengths.65		
Figure	8	(A)	The	amount	of	solubilized	heme	was	quantified	after	10	minutes	for	NP-40	and	the	TXn	detergents	using	the	pyridine-ferrochrome	method.	The	amount	of	solubilized	heme	increased	in	a	sigmoidal	pattern	with	increasing	PEO	lengths.	Measurements	were	taken	in	triplicate	with	reported	standard	deviations	for	each	graph.	(B)	The	percentage	of	heme	crystallization	was	determined	after	120	minutes	of	incubation	with	the	TXn	detergents	(circles)	revealing	a	similar	pattern	to	the	amount	of	heme	solubilized	by	the	detergent	mediators.	NP-40	(triangle)	resulted	in	much	faster	kinetics	with	a	greater	amount	of	crystalized	heme	formed	at	120	minutes	compared	to	all	other	detergents.4		
0 5 10 15 20 25 30
0
10
20
30
40
50
Average PEO Chain Length (n)
So
lu
bi
liz
ed
 h
em
e 
(n
m
ol
)
0 5 10 15 20 25 30
0
20
40
60
80
Average PEO Chain Length (n)
%
 H
em
e 
cr
ys
ta
lli
za
tio
n
A B 
		 28	
Previous	studies	with	synthetic	NLDs	and	phospholipids	can	be	used	to	help	rationalize	detergent-mediated	heme	solubilization	and	crystallization.		In	synthetic	NLDs,	amphiphilic	heme	has	been	shown	to	rapidly	partition	within	the	hydrophobic	interior	of	the	lipid	particle.54	The	Triton	X	detergents	differ	only	in	the	hydrophilic	portion	of	the	molecule,	which	implies	the	correlation	between	increased	heme	crystallization	and	PEO	chain	length	is	dependent	upon	interactions	that	occur	with	heme	and	the	hydrophilic	surfaces.		Therefore,	this	trend	could	arise	from	the	rate	at	which	heme	is	sequestered	into	the	hydrophobic	portion	of	the	detergent	aggregate,	where	β-hematin	formation	is	proposed	to	occur.		For	the	Triton	X	detergents,	a	greater	number	of	PEO	units	corresponds	to	a	smaller	aggregation	number;	therefore,	the	aggregates	should	be	relatively	equally	packed	and	of	similar	size.70	However,	a	longer	hydrophilic	chain	would	result	in	a	greater	probability	for	the	heme	to	interact	with	the	PEO	units	and	be	sequestered	into	the	hydrophobic	core	at	a	more	rapid	rate	compared	to	detergents	with	shorter	hydrophilic	chains.	This	is	analogous	to	synthetic	NLDs	and	phospholipids,	where	lower	activation	barriers	for	heme	crystallization	are	observed	for	lipids	with	less	rigid	surfaces.71,	72	The	increased	fluidity	of	Triton	X	detergents	with	smaller	PEO	chains,	as	indicated	by	the	phase	transition	temperatures,	allows	for	faster	organization	of	heme	molecules,	resulting	in	dimer	assembly	and	crystal	nucleation.			
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Conclusions	and	Future	Directions	
	 Since	hit	rates	in	our	target-based	β-hematin	inhibition	assay	were	vastly	improved	compared	to	other	assays,	we	set	out	to	understand	this	discrepancy	through	the	use	of	detergents.		Detergents	have	been	identified	as	mediators	of	β-hematin	formation	at	rates	comparable	to	that	found	within	the	parasite,	though	no	systematic	investigation	into	the	effects	of	detergent	identity	on	heme	crystallization	has	previously	been	reported.		Through	evaluating	detergents	on	their	ability	to	form	β-hematin	under	biologically	relevant	conditions,	we	can	better	understand	the	mechanism	of	the	target-based	high-throughput	in	vitro	assay	previously	developed	in	our	lab.61	Physicochemical	properties	of	the	lipophilic	mediator	have	a	great	affect	on	β-hematin	formation,	including	charge	of	the	polar	head	group,	the	hydrophobic	core,	hydrophilic	chain	length,	and	temperature.		Detergent	nanostructures	provide	a	hydrophilic-hydrophobic	interface	that	favors	early	heme	partitioning	and	solubilization	into	the	lipid	layer.	Heme	molecules	are	thus	able	to	orient	in	a	suitable	manner	that	reduces	the	energy	barrier	required	to	allow	axial	water	removal	and	eventually	facilitating	Fe(III)PPIX	interaction	through	reciprocal	iron-propionate	bonds.		These	nanostructures	are	able	to	closely	mimic	the	hypotheses	for	hemozoin	crystallization	and	growth	along	the	lipid	subphase	found	either	as	NLDs	in	the	digestive	vacuole	or	as	phospholipids	in	the	digestive	vacuole	membrane.56,	68	Therefore,	these	detergents	could	be	utilized	as	surrogates	to	study	in	vitro	β-hematin	formation.		
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	 Formation	by	NP-40	was	found	to	most	closely	resemble	the	biological	processes	and	was	used	as	the	biological	mimic	in	the	β-hematin	inhibition	assay	previously	developed	in	our	laboratory.61	However,	due	to	this	product	being	discontinued	from	the	manufacturer,	an	alternative	must	be	determined	for	additional	use	of	this	screening	method.		This	in	depth	study	of	the	ideal	detergent	physicochemical	properties	will	aid	in	future	determination	of	an	NP-40	substitute	that	closely	mimics	the	biological	mechanism.		With	the	limited	number	of	detergents	capable	of	mediating	β-hematin	formation,	mixtures	of	detergents	can	also	be	examined	for	biological	relevance.			
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Chapter	III	
	
TARGET	VALIDATION	OF	HEMOZOIN	INHIBITION	
	
Background	
Target-based	HTS	can	be	combined	with	antimalarial	phenotypic	screens	in	order	to	improve	the	overall	drug	discovery	process.		When	these	two	types	of	screens	are	conducted	sequentially,	the	number	of	compounds	that	progress	through	the	drug	pipeline	is	then	decreased	to	a	manageable	level.		However,	even	if	a	compound	exhibits	activity	in	both,	it	is	still	difficult	to	verify	that	its	activity	is	specific	to	the	target	of	interest	and	not	an	unrelated	biological	pathway.		Without	target	validation,	one	cannot	be	certain	of	the	drug	target	in	the	parasite,	which	ultimately	hinders	rational	drug	design.	To	circumvent	this,	it	is	necessary	to	validate	the	biological	target	first	with	an	in	vitro	biological	system	of	P.	falciparum	infected	erythrocyte	culture.		While	there	are	a	variety	of	reported	β-hematin	inhibition	assays,58,	60-62,	73	currently	there	is	only	a	single	method	for	target	validation	of	hemozoin	inhibition,	which	was	recently	developed	by	our	collaborators.74	This	not	only	allows	us	to	evaluate	our	in	house	target-based	assay,	but	it	also	leads	to	more	efficient	hit	compound	progression	towards	a	successful	antimalarial.			
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Part	I.	Assessment	of	Hemozoin	Formation	Inhibition	by	Known	Antimalarials	
	
Introduction		
Hemozoin	inhibitors	prevent	crystal	formation	in	the	parasite,	resulting	in	a	build	up	of	lethal	Fe(III)PPIX.		By	observing	this	alteration	of	heme	species	we	are	able	to	establish	if	hemozoin	formation	is	the	target	for	a	specific	drug	compound.	An	increase	in	the	ratio	of	intracellular	free	heme	to	hemozoin	with	increasing	drug	concentration,	corresponding	with	death	of	the	parasite,	would	suggest	the	compound	inhibits	crystal	formation.	On	the	other	hand,	if	an	elevated	drug	concentration	does	not	alter	the	heme	to	hemozoin	ratio,	but	the	parasite	still	dies,	then	another	biological	mechanism	is	likely	the	in	vivo	target.		Combrinck	et	al.	provided	the	first	direct	evidence	that	CQ	prevents	hemozoin	formation	within	the	malaria	parasite.		Following	CQ	treatment,	free	heme	levels	rose	within	a	CQ	sensitive	P.	falciparum	strain	(D10)	in	a	dose	dependent	fashion,	correlating	strongly	with	parasite	survival.		Other	suspected	hemozoin	inhibitors	(AQ	and	mefloquine)	similarly	showed	a	rise	in	heme	and	decrease	in	hemozoin	levels	compared	to	the	control	culture	(without	drug	treatment).		As	expected,	antifolate	compounds,	such	as	PYR	and	the	combination	therapy	sulfanilamide-PYR,	provided	no	significant	perturbation	on	the	levels	of	free	heme	or	hemozoin	in	the	parasite.		
Here,	we	seek	to	evaluate	the	methods	of	this	target	validation	assay	by	assessing	current	antimalarials	with	known	biological	targets.		Consequently,	this	assay	can	be	applied	to	test	for	biological	target	validation	with	the	antimalarial	β-
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hematin	inhibitor	compounds	discovered	as	a	result	of	our	HTS	efforts.		These	results	will	provide	a	smaller	set	of	compounds	with	strong	potential	to	progress	further	with	pharmacokinetic	experiments	and	in	vivo	mouse	model	studies.		
	
Experimental	Methods	
Materials	
The	Plasmodium	falciparum	strains	D6	(Sierra	Leone)	and	C235	(Thailand)	were	generously	donated	by	the	Walter	Reed	Army	Institute	of	Research.	The	3D7	strain,	a	clone	of	the	NF54	isolate,	was	kindly	donated	by	Jacquin	C.	Niles	at	the	Massachusetts	Institute	of	Technology.	The	K1	strain	(Thailand)	of	P.	falciparum	(MRA-159)	was	obtained	through	the	MR4	as	part	of	the	BEI	Resources	Repository,	NIAID,	NIH,	deposited	by	DE	Kyle.		Cell	culture	reagents	including	RPMI-1640	with	L-glutamine,	and	hypoxanthine	(99.5%)	were	obtained	from	Fisher	Scientific.		D-(+)-glucose	(≥	99.5%	GC)	and	2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic	acid	(HEPES)	were	purchased	from	Sigma	Aldrich.	Verapamil	hydrochloride	was	purchased	from	ACROS	Organics	through	Fisher	Scientific.		Human	A+	erythrocytes	(HP1002A)	and	plasma	(HP1013A)	were	obtained	from	Valley	Biomedical	fresh	from	normal	healthy	donors	and	were	prescreened	to	be	negative	for	HBsAG,	HIV	½,	HIV-1	NAT,	HCV,	HCV-NAT,	and	syphilis.	AlbuMAX	I	lipid-rich	bovine	serum	albumin	was	purchased	from	Life	Technologies	and	used	as	a	serum	substitute.			
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Culturing	Plasmodium	falciparum	in	vitro	
Each	strain	of	P.	falciparum	was	cultured	using	a	modified	version	of	the	original	method	by	Trager	and	Jensen.75	Cultures	were	maintained	at	5%	hematocrit	in	human	A+	erythrocytes,	which	was	washed	two	times	with	media	and	used	no	longer	than	one	week.		Culture	medium	was	exchanged	daily	with	A+	erythrocytes	added	to	the	culture	every	other	day	to	maintain	approximately	5%	parasitemia.		Larger	volumes	of	culture	with	higher	parasitemia	levels	were	obtained	through	decreasing	the	hematocrit	(1-2%)	with	more	frequent	medium	exchanges.		Cultures	were	incubated	at	37°C	in	a	pure	gas	mixture	of	5%	O2,	5%	CO2,	and	90%	N2.		Culture	media	for	D6	and	C235	strains	included	RPMI	1640	with	L-glutamine	supplemented	with	25	mM	HEPES,	11	mM	glucose,	29	μM	hypoxanthine,	0.24%	sodium	bicarbonate,	and	10%	human	A+	heat-inactivated	plasma.		The	remaining	strains,	3D7	and	K1,	were	cultured	with	a	serum	substitute,	AlbuMAX	I	(0.5%	w/v).	Culture	integrity	was	monitored	by	blood	smears	stained	with	10%	(v/v)	Giemsa	in	0.1	M	phosphate	buffer	(pH	7.4)	and	visualized	using	a	compound	light	microscope.	Ring	synchronization	was	achieved	by	treating	cultures	with	ten	volumes	of	5%	(w/v)	sorbitol	in	RPMI	media	for	ten	minutes	with	vigorous	shaking,	followed	by	two	washings,	and	resuspension	in	fresh	complete	media.		If	tighter	synchronization	was	desired,	an	additional	sorbitol	treatment	was	conducted	eight	hours	after	the	first.	
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Biological	target	validation	assay	
The	heme	speciation	assay	for	target	validation	was	conducted	using	a	modified	method	previously	described	by	our	collaborators.74	A	P.	falciparum	culture	of	4	mL	packed	cell	volume	at	~5%	parasitemia	was	sorbitol	synchronized	in	the	early	ring	stage	and	resuspended	in	fresh	media	at	2%	hematocrit.		This	single	culture	was	evenly	divided	among	four-25	cm2	culture	flasks	and	treated	with	test	compound	at	0,	0.5,	1,	2,	and	3	times	the	IC50	value	previously	determined	in	the	Malaria	SYBR	Green-I	Fluorescence	based	(MSF)	assay	(Appendix	B).		The	cultures	were	then	incubated	until	the	late	trophozoite	stage	was	reached	(28-32	hours	depending	on	the	specific	strain).		A	sample	of	each	culture	was	removed	to	observe	parasite	morphology	by	microscopic	analysis	and	to	determine	survival	rates	based	on	SYBR	Green-I	fluorescence	relative	to	the	untreated	culture.			At	this	time,	a	saponin	solution	was	added	the	original	sample	(0.05%	(w/v)	final	concentration)	and	mixed	thoroughly	for	two	minutes	to	selectively	lyse	the	erythrocytes	(both	infected	and	uninfected),	leaving	the	parasite	trophozoites	intact.		The	sample	was	centrifuged	for	10	minutes	at	1500	g,	followed	by	two	wash	steps	with	PBS	to	remove	undesired	erythrocyte	hemoglobin,	and	the	black	trophozoite	pellet	was	resuspended	in	1	mL	PBS.		200	μL	was	removed	for	microscopic	analysis	and	trophozoite	counting	before	storage	of	the	remaining	sample	at	-40°C	until	processing.		
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Heme	fractionation	assay		
To	process	the	samples,	the	trophozoites	were	lysed	through	a	single	freeze-thaw	cycle	and	three	technical	replicates	were	prepared	in	1.5	mL	microcentrifuge	tubes	consisting	of	200	μL	samples.	To	each	tube,	100	μL	of	water	and	0.2	M	HEPES	buffer	(pH	7.4)	was	added	and	the	sample	was	sonicated	in	a	water	bath	for	5	minutes	before	centrifugation	(5	minutes	at	16,100	g).		The	hemoglobin	fraction	present	in	the	parasite	was	collected	as	the	supernatant.		To	both	the	pellet	and	the	supernatant,	100	μL	of	4%	SDS	was	added	and	sonicated	for	5	minutes	before	an	additional	30	minute	incubation	at	room	temperature.		100	μL	of	0.3	M	NaCl	and	25%	pyridine	in	0.2	M	HEPES	(pH	7.4)	was	added	to	the	supernatant	and	diluted	with	water	to	the	final	volume	of	1	mL	using	a	volumetric	flask.			
Following	incubation	100	μL	each	of	water,	0.02	M	HEPES	(pH	7.4),	0.3	M	NaCl,	and	25%	pyridine	was	added	to	the	pellet	and	centrifuged	for	5	minutes	at	16,100	g.		The	supernatant	was	removed	and	precisely	diluted	to	1	mL	with	water	in	a	volumetric	flask	and	saved	as	the	free	heme	fraction.	The	second	pellet	consisted	of	the	hemozoin	fraction,	which	was	solubilized	using	100	μL	0.3	M	NaOH.		This	sample	was	sonicated	and	incubated	for	30	minutes	at	room	temperature	before	the	addition	of	0.02	M	HEPES	(pH	7.4),	0.3	M	HCl,	and	25%	pyridine,	followed	by	water	dilution	to	1	mL.			
A	single	200	μL	aliquot	of	each	fraction	was	transferred	to	a	96-well	clear	plate	and	the	absorbance	spectra	was	read	between	300-700	nm	on	a	BioTek	Synergy	H4	Hybrid	Multiwell	Plate	Reader.		The	maximum	absorbance	peak	at	405	
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nm	due	to	the	heme-pyridine	complex	was	recorded	and	used	to	quantify	the	percentages	of	the	heme	species	(host	ingested	hemoglobin,	intercellular	free	heme,	and	hemozoin)	present	in	the	trophozoite	samples.		
	
Results	and	Discussion	
Known	antimalarial	50%	inhibitory	concentrations	
	 Four	antimalarial	compounds	were	chosen	from	the	list	of	chemotypes	that	target	different	parasitic	pathways	(Table	1)	for	testing	in	the	heme	speciation	assay	as	a	method	for	validating	hemozoin	formation	inhibition	in	the	parasite.		The	known	antimalarial	compounds	chosen	included	chloroquine	(CQ),	pyrimethamine	(PYR),	artemisinin	(ART),	and	atovaquone	(ATV)	(Figure	9).		To	begin	our	study,	the	
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Figure	9	Structures	of	known	antimalarial	compounds	used	for	validation	of	various	screening	assays	
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IC50	values	for	these	four	known	antimalarial	compounds	were	determined	using	the	MSF	assay	for	three	biological	replicates.			
	
Determination	of	drug	treatment	concentrations	
	 The	MSF	IC50	values	of	the	four	antimalarial	compounds	were	used	to	establish	the	drug	concentrations	for	the	heme	speciation	assay.		Typically,	five	concentrations	made	up	a	dose	response	curve,	0,	0.5,	1,	2,	and	3	times	the	MSF	IC50	value	determined	in	the	D6	strain.		Extreme	high	concentrations	above	the	IC50	value	were	included	because	the	drug	incubation	time	is	significantly	reduced	from	that	used	in	the	MSF	assay	(28-32	vs	72	hours),	which	affects	the	concentration	of	drug	required	for	decreased	parasite	survivability	most	likely	due	to	diffusion	effects.	Dose	response	treatment	of	a	culture	of	ring	stage	parasites	incubated	with	
-9 -8 -7 -6
0
20
40
60
80
100
Log [Chloroquine] M
%
 P
ar
as
ite
 S
ur
vi
va
l 32 hr
72 hr
IC50 = 83.4 ± 1.1 nM
IC50 = 8.7 ± 1.1 nM
Figure	10	P.	falciparum	(D6)	survival	rates	following	a	dose	response	treatment	with	CQ.	Cultures	(0.3%	parasitemia)	were	incubated	with	CQ	for	32	hours	(solid	line)	and	72	hours	(dotted	line)	followed	by	the	addition	of	SYBR	Green-I.	DNA-SYBR	Green-I	fluorescence	was	read	(Ex.	488	nm,	Em.	522	nm)	and	reported	as	percent	parasite	survival	when	compared	to	the	control	group	after	72	hours.	Data	represents	the	mean	and	standard	deviation	of	percent	parasite	survival	for	two	experiments	of	triplicate	measurements.		
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CQ	for	32	hours	was	compared	to	72	hours	of	CQ	to	observe	the	discrepancy	of	IC50	values	(83.4	±	1.1	and	8.7	±	1.1	nM,	respectively)	(Figure	10).	If	a	parasite	culture	is	in	the	early	ring	stage,	after	32	hours	of	incubation	time	it	will	be	in	the	late	trophozoite	stage	of	the	first	replication	cycle.	In	comparison,	when	incubated	for	72	hours,	the	parasite	culture	will	have	gone	through	one	complete	replication	cycle	and	should	be	in	the	second	trophozoite	stage	upon	completion.	Due	to	the	longer	incubation	time,	the	drug	has	an	opportunity	eliminate	any	rings	or	trophozoites	that	evaded	death	in	the	first	cycle	and	will	exhibit	a	lower	IC50	value.	Therefore,	when	administering	treatment	in	the	heme	speciation	assay,	higher	drug	concentrations	than	those	determined	from	the	MSF	assay	were	included	to	account	for	the	shorter	assay	incubation	time.		
	
The	effect	of	mechanism	of	action	on	heme	speciation	
	 The	four	known	antimalarials	were	then	subjected	to	the	heme	speciation	assay	to	ensure	this	is	a	valid	method	to	determine	hemozoin	formation	as	the	biological	target	of	the	parasite.		As	predicted,	with	increasing	CQ	concentration,	parasite	viability	decreased	and	the	amount	of	intracellular	free	heme	increased	(Figure	11).	This	gradual	rise	of	intracellular	free	heme	and	decline	of	hemozoin	indicates	that	the	hemozoin	formation	pathway	is	being	perturbed.		These	increased	levels	of	free	Fe(III)PPIX	results	in	lipid	peroxidation,	formation	of	protein	adducts,	and	other	deleterious	effects.76,	77	On	the	other	hand,	PYR,	ART,	and	ATV	are	known	to	target	alternative	drug	pathways	(Table	1)	and	do	not	have	any	impact	on	
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hemozoin	crystal	formation,	thus	can	act	as	negative	control	compounds	in	this	assay.		Following	increasing	doses	of	drug	treatment,	these	three	antimalarial	compounds	still	resulted	in	decreased	parasite	viability;	however,	there	was	no	significant	change	of	the	intracellular	free	heme	or	hemozoin	from	basal	levels	(Figure	12).	This	indicates	that	there	is	another	primary	source	of	activity	that	when	perturbed,	does	not	affect	the	parasite	heme	speciation.	By	using	antimalarials	with	known	biological	targets,	we	were	able	to	provide	evidence	that	this	assay	can	be	used	for	target	validation	of	our	HTS	assays	probing	antiplasmodial	activity	as	well	as	β-hematin	inhibition.	
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Figure	11	The	species	of	heme	were	determined	following	treatment	with	five	increasing	concentrations	of	CQ	using	the	heme	fractionation	assay	described.	(A)	Parasite	viability	using	SYBR	Green-I	fluorescence	is	plotted	on	the	right	y-axis	(red	curve).		The	IC50	calculated	from	this	curve	was	~	70	nM.		The	percentage	of	free	heme	is	plotted	on	the	left	y-axis		(blue	curve)	with	the	IC50	of	this	curve	approximately	equal	to	70	nM	also.	Bar	graphs	illustrate	the	percentage	of	(B)	host	ingested	hemoglobin,	(C)	intracellular	free	heme,	and	(D)	hemozoin.		Data	points	represent	the	average	and	standard	deviation	of	three	measurements.			
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The	effect	of	strain	variation	on	heme	speciation	
An	additional	approach	to	validate	the	heme	speciation	assay	was	through	comparing	dose	response	CQ	treatment	between	a	CQ	sensitive	(D6)	and	a	multi-drug		(CQ,	PYR,	and	mefloquine)	resistant	(C235)	strain	of	P.	falciparum.	The	C235	strain	required	almost	ten	times	the	concentration	of	CQ	in	order	to	observe	a	50%	decrease	in	parasite	growth,	which	also	correlated	with	a	delayed	rise	in	free	heme	levels	(Figure	13).		This	shows	that	our	assay	is	robust	in	screening	for	drugs	that	are	specific	for	hemozoin	inhibition	as	we	are	still	able	to	see	the	changes	in	free	heme	percentages	in	resistant	strains,	but	just	not	as	drastically	as	with	the	CQ	sensitive	strain.			
Verapamil	(VPL)	is	a	calcium	channel	blocker	that	has	been	reported	to	reverse	CQ	resistance	through	preventing	the	efflux	of	CQ	by	PfCRT.78	We	determined	that	VPL	does	not	affect	parasite	viability	at	concentrations	less	than	1.6	µM	(95%	confidence	interval)	(data	not	shown).	Therefore,	0.8	µM	VPL	was	chosen	
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Figure	12	Heme	speciation	was	performed	on	three	additional	antimalarials	with	known	biological	targets	to	ensure	the	validation	assay	is	reliable	in	predicting	hemozoin	inhibitors.	Following	treatment	with	(A)	PYR,	(B)	ART,	or	(C)	ATV,	parasites	were	no	longer	viable,	but	the	intracellular	free	heme	found	in	the	culture	remained	constant	when	compared	to	no	drug	treatment	controls.		These	three	antimalarial	compounds	can	be	used	as	negative	controls	in	the	heme	speciation	assay.		
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as	an	effective	resistance	reversal	concentration.		A	culture	of	C235	(5%	parasitemia)	was	incubated	with	VPL	for	30	minutes	prior	to	CQ	treatment	and	collected	after	32	hours	at	the	late	trophozoite	stage	for	analysis.		This	resulted	in	parasite	survival	IC50	and	free	heme	levels	similar	to	values	observed	with	CQ	treated	D6	cultures.		In	each	of	these	cases,	the	point	of	overlap	between	free	heme	and	parasite	survival	dose	response	curves	coincides	with	the	biological	IC50	for	the	specific	strains.		Furthermore,	the	reversal	of	drug	resistance	and	reestablished	trends	seen	in	the	heme	speciation	assay	indicates	that	this	is	a	valid	method	for	determining	hemozoin	inhibition	as	the	drug	target	in	a	parasite	culture.		
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Figure	13	A	multidrug	resistant	strain	of	P.	falciparum	(C235)	was	treated	with	increasing	concentrations	of	CQ.		The	IC50	value	calculated	from	parasite	survival	(right	y-axis,	sold	red	line)	is	shifted	higher	compared	to	Figure	11A,	indicating	that	this	culture	has	a	greater	resistance	to	the	drug,	CQ.		Correspondingly,	the	intracellular	free	heme	(left	y-axis,	sold	blue	line)	was	not	perturbed	until	higher	concentrations.		When	the	multidrug	resistant	culture	was	subjected	to	0.8	µM	verapamil,	a	compound	known	to	reverse	resistance,	the	parasite	survival		(dotted	red	line)	and	percent	free	heme	(dotted	blue	line)	were	restored	to	levels	observed	with	the	drug	sensitive	strain,	D6.			
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Conclusions	and	Future	Directions	
	 To	validate	the	results	obtained	in	our	HTS	efforts,	we	must	be	able	to	confirm	biological	target	activity	within	a	parasite	culture.	Therefore,	it	was	first	necessary	to	develop	and	validate	a	method	of	discerning	hemozoin	inhibitors	through	the	use	of	known	antimalarial	compounds.	The	heme	speciation	assay	was	tested	using	a	hemozoin	inhibitor	(CQ)	and	other	non-hemozoin	inhibitors	(PYR,	ART,	and	ATV),	resulting	in	a	rise	in	free	heme	levels	only	with	CQ.	We	determined	that	this	assay	is	specific	for	the	hemozoin	formation	pathway	by	comparing	a	drug	sensitive	strain	of	P.	falciparum	(D6)	to	a	multidrug	resistant	strain	(C235).		The	increased	levels	of	free	heme	as	a	result	of	CQ	treatment	corresponded	with	the	antiplasmodial	IC50	values.	However,	when	a	resistance	reversal	compound	(VPL)	was	applied	to	the	resistant	strain,	both	free	heme	and	antiplasmodial	IC50	values	were	restored	to	those	seen	with	the	drug	sensitive	strain.		These	combined	results	indicate	that	the	method	of	determining	hemozoin	formation	perturbation	in	a	parasite	culture	is	effective	and	can	be	utilized	to	evaluate	the	hit	compounds	in	our	HTS	efforts.		
Throughout	these	experiments,	we	observed	that	the	D6	strain	of	P.	
falciparum	exhibited	basal	intracellular	free	heme	percentages	around	10%	prior	to	drug	treatment.	However,	when	other	P.	falciparum	strains	tested	(Figure	14)	exhibited	basal	free	heme	levels	of	closer	to	5%.		This	difference	could	indicate	that	heme	tolerance	is	dependent	on	the	specific	strain	type	and	future	experiments	should	look	into	differences,	such	as	oxidative	stress	tolerance,	between	strains.			
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Figure	14	Basal	intracellular	free	heme	percentages	in	control	cultures	of	six	different	Plasmodium	falciparum	strains	
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Part	II:	Validation	of	Hemozoin	Inhibition	from	In	Vitro	Target-Based	Screens		
	
Introduction	
In	2009,	GlaxoSmithKline	(GSK)	screened	their	library	of	approximately	2	million	compounds	against	the	CQ	sensitive	P.	falciparum	3D7	strain	by	measuring	the	amount	of	Plasmodium	lactate	dehydrogenase	enzyme	present	following	drug	treatment.79	This	screen	resulted	in	13,533	compounds	that	inhibited	parasite	growth	above	an	80%	threshold	compared	to	an	untreated	culture.		As	a	part	of	an	“open	innovation	strategy,”	the	structures	and	pharmacological	data	of	these	hit	compounds	were	released	to	the	public	in	order	to	facilitate	collaborations	among	large	corporations	and	academia	and	were	encouraged	to	test	these	results	in	target-based	assays.80,	81		
In	another	effort,	the	MMV	was	established	in	1999	to	enable	the	discovery	of	new,	effective,	and	affordable	antimalarial	compounds.		Through	the	support	of	MMV,	HTS	of	in	vitro	antimalarial	activity	resulted	in	over	20,000	hit	compounds.79,	
82,	83	The	structures	for	each	of	these	compounds	have	since	been	deposited	in	a	free	open	access	repository,	the	ChEMBL	neglected	tropical	diseases	archive	(https://www.ebi.ac.uk/chemblntd).		To	encourage	an	open	innovation	strategy,	MMV	selected	400	of	these	hits	that	well	represented	the	wide	chemical	diversity	observed	and	deemed	it	the	Malaria	Box,	which	was	sent	to	a	variety	of	labs	across	the	world.		While	these	compounds	were	reported	to	be	potent	in	vitro	antiplasmodial	compounds,	their	specific	drug	target	remained	unknown.			
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Experimental	Methods	
Materials	
	 The	Tres	Cantos	Antimalarial	Set	(TCAMS)	of	compounds	that	resulted	in	>90%	β-hematin	inhibition	in	our	original	screen	were	supplied	to	our	lab	(225	out	of	250	reported)	in	384-well	Greiner	clear,	flat-bottom	plates	by	GSK	in	duplicate.	Each	plate	consisted	of	the	compound	dissolved	in	DMSO	so	that	a	concentration	dependent	curve	was	observed	across	the	rows.		The	overall	DMSO	percentage	remained	constant	in	each	well.	Columns	6	and	18	were	left	empty	for	addition	of	positive	and	negative	controls.		The	MMV	Malaria	Box	set	of	400	compounds	was	provided	at	10	mM	concentrations	in	96-well	plates	in	a	total	of	30	µL	for	each	compound.	The	compounds	were	acoustically	transferred	to	384-well	assay	plates	for	both	the	β-hematin	inhibition	screen	and	the	antiplasmodial	screen	using	a	Labcyte	ECHO	555	liquid	handler.	Columns	1,2,	23,	and	24	were	used	as	positive	and	negative	controls	for	each	assay	plate.		Miguel	Quiliano	at	the	University	of	Navarra	synthesized	the	aryl	amino	alcohol	derivatives.	The	compounds	were	dissolved	in	DMSO	to	make	a	10	mM	solution	and	transferred	to	384-well	assay	plates	using	acoustic	delivery.		
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Results	and	Discussion	
GlaxoSmithKline	Tres	Cantos	Antimalarial	Set	screen	
	 With	collaborative	efforts,	GSK	graciously	provided	us	with	13,229	of	their	antiplasmodial	compounds	to	test	in	our	in	vitro	β-hematin	inhibition	assay	at	22	µM	final	assay	concentration,	the	β-hematin	IC50	value	of	AQ.	Compounds	that	inhibited	β-hematin	growth	by	more	than	90%	compared	to	positive	(IC100	of	AQ)	and	vehicle	(0.25%	DMSO)	controls	were	deemed	as	“hits.”1	Even	with	this	extremely	stringent	cutoff,	250	antiplasmodial	compounds	were	found	to	be	active	against	β-hematin	inhibition.		Of	these	hits,	GSK	provided	225	compounds	that	were	
Figure	15	A	dose	response	titration	was	performed	on	the	top	225	GSK	antiplasmodial	compounds	against	β-hematin	inhibitory	activity.		50%	inhibitory	concentrations	were	calculated	from	duplicate	measurements.		The	number	of	compounds	that	fell	into	each	bin	of	IC50	values	was	reported.		Of	the	225	compounds,	80%	exhibited	potent	activity	(<30	µM)	when	compared	to	known	positive	control	β-hematin	inhibitors.	1	
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then	subjected	to	dose	response	curves	in	duplicate	with	final	drug	concentrations	ranging	between	0.1	and	100	µM.		This	resulted	in	more	than	80%	of	the	top	225	compounds	having	β-hematin	IC50	values	less	than	30	µM	(Figure	15),	which	is	comparable	to	control	compounds	of	CQ	and	AQ	(IC50	=	48.7	and	21.0	µM,	respectively).		This	high	potency	and	low	false	positive	rate	(2%)	indicates	that	our	
in	vitro	target-based	HTS	assay	is	robust	and	extremely	useful	in	prioritizing	compounds	within	libraries.		See	Appendix	C	for	full	screening	results.		
	 	
With	a	focused	list	of	220	compounds	that	were	confirmed	to	be	active	in	both	the	parasite	survivability	and	β-hematin	inhibition	assays	(<50	µM),	we	sought	to	validate	hemozoin	as	the	biological	target	responsible	for	parasite	death	using	the	heme	speciation	assay	described	in	Part	I	of	this	chapter.		Of	these	225,	15	were	commercially	available	at	the	time	of	purchase	(14	active,	one	not	active)	and	were	acquired	through	ChemBridge,	ChemDiv,	or	Vitas-M	Laboratory	Ltd.	at	purities	>90%.	A	culture	of	synchronized	rings	was	treated	with	each	compound	at	concentrations	of	0,	0.5,	1,	2,	and	3	times	the	IC50	values	reported	for	the	3D7	P.	
falciparum	strain	by	Gamo	et	al.,79	the	parasites	were	isolated,	and	the	three	parasite	heme	species	were	fractionated.		To	illustrate	an	example	compound,	the	dose	response	treatment	of	TCMDC-125529	led	to	a	rise	in	free	heme	levels	with	a	corresponding	decline	in	hemozoin	(Figure	16).	These	observations	were	similar	to	those	of	CQ,	confirming	its	activity	against	the	hemozoin	formation	pathway.		A	slight	increase	in	parasite	hemoglobin	was	observed	at	the	higher	drug	
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concentrations,	most	likely	due	to	build	up	of	undigested	hemoglobin	by	declining	parasites.		
	
The	antiplasmodial	compound	TCMDC-124168	was	found	to	be	inactive	in	the	β-hematin	inhibition	assay	and	thus,	was	used	for	validation	of	a	negative	test	compound,	similar	to	PYR.		When	a	culture	was	treated	with	increasing	drug	concentration,	parasite	death	was	observed,	but	there	were	no	changes	in	the	free	heme	or	hemozoin	levels	(Figure	17).		This	again	confirms	the	effectiveness	of	our	heme	speciation	assay	in	validating	this	mode	of	action	not	only	with	compounds	
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Figure	16	A	culture	of	P.	falciparum	(D6)	was	subjected	to	the	GSK	compound	TCMDC-125529	at	four	different	concentrations	for	32	hours.	Following	incubation,	the	trophozoites	were	isolated	from	host	erythrocytes.		Due	to	differences	in	solubility	host	ingested	hemoglobin	(B),	intracellular	free	heme	(C),	and	hemozoin	(D)	can	be	fractionated	and	quantified.		The	decrease	in	parasite	survival	(A,	red)	correlated	with	an	increase	in	free	heme	(A,	blue)	confirming	that	this	specific	compound	perturbs	the	hemozoin	formation	pathway.	The	IC50	for	%	free	heme	was	60	±	3	nM	that	corresponded	well	to	the	parasite	survival	IC50	of	70	±	2	nM.1			
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with	known	biological	targets,	but	also	for	unconfirmed	hit	compounds	from	our	target-based	screen.		
		 Thirteen	of	the	fourteen	TCAMS	compounds	tested	in	the	heme	speciation	assay	were	confirmed	to	inhibit	hemozoin	formation	in	P.	falciparum	(Table	2Error!	
Reference	source	not	found.),	demonstrating	the	effectiveness	of	our	HTS	assay	in	predicting	hemozoin	inhibitors.		This	is	largely	due	to	our	HTS	assay	conditions	having	strong	similarity	to	the	biological	environment	of	the	parasite,	especially	when	compared	to	other	β-hematin	inhibition	assays.62	While	the	remaining	two	compounds	tested	were	potent	β-hematin	inhibitors	in	our	target-based	screen,	they	did	not	cause	any	changes	in	the	levels	of	heme	species	when	tested	in	a	parasite	culture	and	thus,	most	likely	have	an	alternative	primary	drug	target.		These	types	of	compounds	may	still	be	hemozoin	inhibitors,	which	can	explain	their	activity	in	our	β-hematin	target-based	screen,	but	only	secondarily	to	another	
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Figure	17	The	negative	control	compound	from	the	GlaxoSmithKline	library,	TCMDC-124168,	was	introduced	to	a	parasite	culture.	Following	heme	fractionation,	there	was	no	different	in	free	heme	or	hemozoin	percentages	at	increasing	concentrations.	Since	this	did	not	elicit	any	β-hematin	activity	in	our	target-based	screen,	we	can	again	validate	our	methods	for	determining	hemozoin	inhibition	activity.1			
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biological	target,	which	can	only	be	determined	by	testing	compounds	in	a	parasite	culture	rather	than	in	a	non-cell	based	assay.		This	set	of	compounds	was	the	first	of	three	compound	libraries	that	we	tested	for	antiplasmodial	activity,	in	vitro	β-hematin	activity,	and	then	validated	for	the	hemozoin	target	in	order	to	parse	out	the	most	promising	candidates	for	novel	antimalarial	hemozoin	inhibitors	from	such	a	vast	chemical	library.		
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Structure GSK	Identifier
β-hematin	IC50	
(µM)a
3D7	IC50		MSF	
Assay	(nM)b
Δ	Free	Heme	(%)
TCMDC-124168 Not	active 991 0.4	±	3.1
TCMDC-125274 9.7	±	0.5 1090 4.3	±	3.5
TCMDC-125529 12.9	±	2.4 830 20.4	±	5.4
TCMDC-125600 16.0	±	0.9 168 23.1	±	1.0
TCMDC-125577 27.7	±	4.4 524 27.7	±	4.2
TCMDC-123486 13.7	±	3.4 512 28.2	±	7.1
TCMDC-125788 18.4	±	3.0 761 32.8	±	4.58
TCMDC-125671 7.8	±	1.9 614 33.1	±	2.6
TCMDC-124822 16.8	±	1.8 874 37.7	±	4.0
TCMDC-123692 17.5	±	1.5 814 39.6	±	7.0
TCMDC-124421 16.6	±	0.6 718 39.8	±	23.7
TCMDC-125530 8.4	±	1.0 659 39.8	±	3.1
TCMDC-124969 25.1	±	3.0 647 45.8	±	8.4
TCMDC-124423 14.3	±	1.3 378 48.4	±	13.2
TCMDC-124972 14.5	±	2.8 1054 84.5	±	3.1
a	Average	mean	and	standard	deviation	of	two	replicates
b	Reported	values	from	Gamo	et	al.
Table	2	The	GSK	TCAMS	compounds	tested	in	the	heme	speciation	assay	to	validate	activity	against	hemozoin	formation1	
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Medicines	for	Malaria	Venture	Malaria	Box	screen		
	 In	collaborative	efforts,	the	Malaria	Box	set	of	400	compounds	was	provided	by	MMV	and	screened	for	β-hematin	inhibitory	activity	at	a	final	concentration	of	22	µM.		This	screen	resulted	in	ten	compounds	with	greater	than	50%	inhibition	relative	to	positive	(IC100	of	AQ)	and	vehicle	(0.25%	DMSO)	controls.2	Dose	response	activity	was	tested	for	these	ten	compounds,	which	indicated	IC50	values	between	8.7	and	22.7	µM	(Table	3).	Again,	these	β-hematin	inhibitory	activities	observed	were	very	potent	compared	to	the	known	hemozoin	inhibitors,	CQ	and	AQ.				
	 The	set	of	400	Malaria	Box	compounds	were	additionally	screened	in	the	MSF	assay	against	both	D6	and	C235	P.	falciparum	strains.		The	IC50	values	obtained	ranged	from	135	–	2165	nM	for	the	CQ	sensitive	strain	and	156	–	3469	nM	for	the	multidrug	resistant	strain	(Table	3).	These	values	were	comparable	to	those	reported	against	the	CQ	sensitive	3D7	strain	found	in	the	open	access	ChEMBL	database.			
	 However,	simply	because	these	ten	compounds	were	highly	potent	in	the	target-based	β-hematin	activity	screen	as	well	as	the	parasite	survivability	screen,	the	mechanism	of	action	within	a	parasite	culture	can	not	be	confirmed.		Thus,	each	of	the	commercially	available	hits	(nine	out	of	ten)	was	subjected	to	the	heme	speciation	assay	for	target	validation	resulting	in	seven	confirmed	as	hemozoin	inhibitors	in	this	cell-based	assay.	This	was	observed	through	a	significant	(p	<	0.05)	increase	in	free	heme	levels	from	baseline,	corresponding	to	decreases	in	hemozoin	and	parasite	survival.	Parasite	morphology	by	microscopy	analysis	confirmed	that	
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Table	3	Medicines	for	Malaria	Venture	Malaria	Box	compounds	tested	for	β-hematin	inhibitory	activity,	antiplasmodial	activity	against	a	drug	sensitive	and	a	drug	resistant	parasite	strain,	and	hemozoin	inhibitory	activity	in	a	drug	sensitive	parasite	culture.2	Compounds	are	grouped	based	on	similar	scaffold.	
Structure MMV	Identifier
β-hematin	IC50	
(µM)a
D6	IC50		MSF	
Assay	(nM)a	
C235	IC50		MSF	
Assay	(nM)a	
SIb
Δ	Free	Heme	
(%)
MMV011895 12.2	±	2.0 135	±	4 156	±	6 1.2 0.2	±	3
MMV007384 10.6	±	2.6 2165	±	151a 3469	±	24b 1.6 18	±	6
MMV666607 22.7	± 1.5 260	±	23 458	±	28 1.8 26	±	2
MMV006767 14.8	±	1.7 782	±	35 1564	±	77 2.0 35	±	7
MMV665888 13.1	±	2.5 1410	±	47 1305	±	98 0.9 28	±	2
MMV665799 16.0	±	2.3 1639	±	23 2765	±	34 1.7 49	±	2
MMV020750 9.1	±	2.1 366	±	15 466	±	22 1.3 0.3	±	3
MMV007273 8.7	±	2.1 262	±	62 351	±	2 1.3 21	±	2
MMV000753 14.0	±	4.9 1212	±	4 1609	±	77 1.3 21		±	4
MMV666689 15.6	±	2.5 465c NT NA NT
a	Average	mean	and	standard	deviation	of	two	replicates	from	commercially	purchased	compounds
b	Sensitivity	index	for	resistance	defined	as	IC50	from	drug	sensitive	strain/IC50	value	of	drug	resistant	strain
c	Value	from	a	single	measurement,	compound	provided	by	MMV
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the	control	culture	was	indeed	collected	at	the	late	trophozoite	stage,	but	the	test	compounds	at	the	upper	concentration	levels	were	either	not	visually	present,	exhibited	punctate	morphologies,	or	were	halted	in	the	ring	stag.	Again,	this	overall	hit	rate	(1.75%)	of	confirmed	mechanism	of	action	in	a	parasite	culture	indicates	that	our	assay	has	a	greater	predictability	compared	to	another	high	throughput	β-hematin	screens	that	only	reported	hit	rates	of	0.1%.62	By	observing	the	distribution	of	Fe(III)PPIX	following	drug	treatment	we	were	able	to	gain	more	insight	into	the	hemozoin	formation	mechanism	of	inhibition.	
	 The	Malaria	Box	compounds	identified	in	this	screen	are	reflective	of	previously	reported	β-hematin	inhibitor	scaffolds.84	The	term	pharmacophore	describes	the	core	structure	of	a	molecule	that	is	most	likely	responsible	for	biological	activity	against	or	binding	to	the	target.85	MMV007384,	MMV011895,	and	MMV666607	all	fit	into	the	category	of	benzimidazole	compounds,	which	have	been	found	to	be	a	potent	scaffold	in	various	β-hematin	in	vitro	screens.	Camacho	et	al.	incorporated	nitrofuran	into	several	benzimidazole-based	structures	and	found	efficacy	on	par	with	that	of	CQ.86	In	addition	to	this	scaffold	expressing	activity	in	both	CQ	sensitive	and	multidrug	resistant	strains	of	P.	falciparum,	it	can	now	be	described	as	having	tendency	towards	the	hemozoin	inhibition	pathway.		Subsequent	testing	of	analogues	is	required	in	structure	activity	relationship	studies	to	increase	predictability	of	the	biological	target	for	the	general	benzimidazole	scaffold.			
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	 The	quinoline	scaffold	was	identified	in	our	screen	of	the	Malaria	Box	set	in	a	single	compound,	MMV006767.	Quinoline	compounds	are	perhaps	the	most	well	known	and	investigated	β-hematin	inhibiting	scaffold	due	to	the	potent	activity	of	the	quinoline	derivative,	CQ,	against	drug	sensitive	strains	of	P.	falciparum.62,	73	Even	with	the	widespread	drug	resistance	against	CQ,	the	quinoline	scaffold	remains	effective	since	the	mechanism	of	resistance	is	unrelated	to	the	mechanism	of	action.87	Furthermore,	it	was	found	that	drug	resistance	is	compound	specific,	allowing	quinoline	derivatives	to	still	be	potent	drug	candidates.88		
	 Two	benzamide	analogues	(MMV665799	and	MMV665888)	were	identified	as	β-hematin	inhibitors	from	the	Malaria	Box	set,	as	seen	with	this	scaffold	in	other	HTS	efforts.82,	84	In	addition,	benzamide	compounds	have	previously	been	identified	as	inhibitors	of	the	P.	falciparum	pyrimidine	biosynthetic	enzyme	dihydroorotate	dehydrogenase.89	Therefore,	this	may	be	a	good	scaffold	to	optimize	as	it	has	been	shown	to	target	two	distinct	biological	pathways,	which	can	improve	efficacy	and	decrease	the	chance	for	resistance	to	develop.		Recently,	efforts	have	been	focused	on	combination	therapies,	which	include	treatment	by	two	antimalarial	compounds	known	to	inhibit	distinct	pathways	and	at	distinct	stages	of	the	life	cycle.	If	this	scaffold	inhibits	two	biological	pathways,	a	similar	effect	may	be	possible	with	a	single	compound,	which	would	decrease	overall	cost	of	treatment	while	maintaining	efficacy.		
	 Here,	the	triaryl	imidazole	scaffold	was	as	identified	as	active	against	β-hematin	formation	and	parasite	growth,	which	corresponds	with	our	previous	
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HTS.84	Two	of	the	three	triaryl	imidazole	β-hematin	inhibitors	(MMV000753	and	MMV007273)	were	confirmed	to	be	active	against	the	parasite	hemozoin	formation	pathway.	However,	MMV020750	did	not	result	in	any	changes	to	the	parasite	heme	speciation,	possibly	due	to	its	increased	hydrophilicity	compared	to	the	other	two	triaryl	imidazole	compounds.	According	to	ChemDraw	Professional	15.0,	MMV020750	has	a	calculated	Log	P	of	2.86	compared	to	5.92	and	5.20	for	MMV000753	and	MMV007273,	respectively.	The	lower	partition	coefficient	indicates	that	MMV020750	is	less	likely	to	interact	with	a	lipophilic	environment,	causing	it	to	be	less	likely	to	inhibit	hemozoin	formation,	a	lipid	mediated	process.		The	remaining	hit	compound	from	this	screen,	MMV666689,	is	similar	to	the	triaryl	imidazole	scaffold	with	some	activity	against	late-stage	gametocytes.90	
	 	These	results	were	the	first	published	β-hematin	inhibition	specific	data	for	the	Malaria	Box	collection.	Ten	potent	inhibitors	of	β-hematin	formation	were	identified,	with	seven	of	the	nine	commercially	available	compound	validated	for	targeting	the	hemozoin	formation	pathway.		The	high	validation	rate	indicates	that	the	conditions	of	our	in	vitro	β-hematin	inhibition	assay	well	represent	the	parasite	environment	of	hemozoin	formation.		These	seven	inhibitors	will	undergo	additional	testing	to	determine	pharmacokinetics	of	each	compound	and	those	with	acceptable	properties	will	continue	on	for	testing	of	in	vivo	efficacy	in	the	P.	berghei	mouse	model.		
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Library	of	aryl	amino	alcohols	
	 On	a	small	scale,	a	set	of	aryl	amino	alcohols	were	evaluated	for	antiplasmodial	and	β-hematin	activity	as	this	scaffold	has	previously	been	shown	to	exhibit	strong	antimalarial	and	pharmacokinetics	properties.91	Current	antimalarial	drugs	with	amino	alcohol	moieties	as	a	pharmacophore	include	quinine,	mefloquine,	lumefantrine,	and	halofantrine.3	Our	collaborators	at	the	University	of	Navarra	synthesized	a	set	of	twelve	1-aryl-3-substituted	propanol	derivatives	(APD)	to	uncover	a	novel	compound	of	this	chemotype,	while	understanding	the	mechanism	of	action.	Previous	in	silico	studies	demonstrated	the	putative	target	for	APD	as	the	parasite	enzyme	plasmepsin	II,92	however,	this	failed	to	be	confirmed	experimentally.3	Therefore,	in	the	search	for	a	biological	target,	these	compounds	were	screened	in	our	target-based	β-hematin	inhibition	assay.			
	 The	twelve	APD	were	tested	against	β-hematin	formation	at	concentrations	ranging	between	0	and	200	µM	in	triplicate.		Of	these	twelve	compounds,	three	were	found	to	be	active	(Table	4),	but	with	more	than	half	the	potency	of	the	known	hemozoin	inhibitors.	Furthermore,	the	APD	were	tested	against	both	a	drug	sensitive	and	multidrug	resistant	strain	of	P.	falciparum	at	concentrations	between	0.030	and	25	µM.		All	of	the	compounds	tested	were	found	active	against	both	parasite	strains,	nine	with	SI	values	of	less	than	1.5,	indicating	that	these	compounds	may	act	differently	from	CQ,	due	to	their	high	activity	against	the	CQ-resistant	strain.	Compound	E02	should	be	highlighted	due	to	its	in	vitro	submicromolar	antiplasmodial	values	with	equal	potency	amongst	three	different	
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strains	of	P.	falciparum	(D6,	CQ	sensitive;	C235,	multidrug	resistant;	and	FCR-3,	mefloquine	resistant).3	
	 To	further	explore	the	mechanism	of	action	of	APD,	target	validation	of	the	hemozoin	formation	pathway	was	conducted	for	the	three	β-hematin	inhibitors.		Examination	of	the	three	species	of	parasitic	heme	revealed	that	the	primary	mode	of	action	for	these	three	compounds	is	not	through	inhibiting	hemozoin	formation.		Despite	a	decline	in	parasite	viability	with	increasing	concentration	of	compound,	the	levels	of	free	heme	and	hemozoin	remained	constant	relative	to	untreated	culture.	Therefore,	the	hemozoin	formation	pathway	is	not	the	predominant	mode	of	death	for	these.		The	in	vitro	β-hematin	IC50	values	for	these	three	APD	were	significantly	greater	than	other	previous	“hit	compounds”	from	our	screens.		Therefore,	while	compounds	may	show	slight	activity	in	our	screens,	there	may	be	an	upper	limit	for	that	activity	to	translate	into	a	parasite	culture.		This	hypothesis	can	be	further	explored	through	additional	high-throughput	library	screening	followed	by	biological	target	validation	in	order	to	observe	overall	trends.						
 
Conclusions	and	Future	Directions	
	 In	the	search	for	a	novel	antimalarial,	it	is	promising	that	scaffolds	contribute	to	multiple	drug	target	pathways	within	P.	falciparum.	Due	to	the	increasing	drug	resistance,	a	successful	treatment	will	consist	of	a	combination	therapy,	where	each	drug	would	target	a	distinct	target	and	life	cycle	stage.	This	method	of	treatment	is	being	used	with	artemisinin-based	combination	therapies,	which	are	currently	the	
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Identifier
β-hematin	
IC50	(µM)
a
D6	IC50		MSF	
Assay	(nM)a
C235	IC50		
MSF	Assay	
(nM)a
SIb Structure
E01 NAc 492.0	±	73.6 1046	±	23 2.13
E02 80.7	±	1.7 108.5	±	10.8 132.1	±	0.0 1.22
E03 NA 276.0	±	29.7 413.4	±	2.8 1.50
E04 NA 147.0	±	10.0 232.9	±	1.5 1.58
E05 NA 6316	±	332 7257	±	167 1.15
E06 NA 3728	±	431 3693	±	167 0.99
E07 NA 97.7	±	10.7 144.3	±	11.0 1.48
E08 NA 95.1	±	23.7 168.8	±	14.0 1.77
E09 NA 190.3	±	4.2 277.7	±	53.7 1.46
E10 109.3	±	7.1 84.1	±	2.7 124.3	±	19.9 1.48
E11 101.2	±	7.7 123.4	±	3.2 166.3	±	21.1 1.35
E12 NA 123.1	±	0.4 154.4	±	7.6 1.25
aAverage	and	standard	deviation	of	two	independent	replicates
bSensitivity	index	=	average	IC50	of	drug	sensitive	strain/average	IC50	value	of	drug	resistant	strain
cNot	active
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Table	4	1-aryl-3-substituted	propanol	derivatives	activities	and	structures3	
		 61	
most	effective	antimalarial	medicine	according	to	the	World	Health	Organization.		Discovering	a	single	compound	that	could	simultaneously	inhibit	two	biological	mechanisms	could	decrease	the	cost	and	allow	for	an	overall	simpler	treatment	plan.	Using	combination	therapies,	such	as	a	hemozoin	inhibitor	with	an	antifolate	drug	will	help	prevent	further	development	of	resistance.	We	have	demonstrated	that	this	strategy	could	also	be	effective	with	a	single	antimalarial	compound	that	is	able	to	target	multiple	biological	pathways.		
	 Since	target	validation	is	a	vital	component	to	discovering	a	new	antimalarial,	we	hope	to	be	able	to	improve	the	throughput	of	these	extremely	laborious	experiments.	In	the	current	method,	a	single	drug	dose	response	curve	requires	up	to	one	month	to	grow	enough	parasites	and	process	all	the	samples.		This	is	not	a	feasible	time	frame	for	large	screening	efforts.		With	our	collaborators,	we	developed	a	plate	method	for	target	validation;	however,	it	requires	extremely	careful	transfer	steps,	potentially	confounding	signal	between	the	different	heme	species.93	Alternatively,	the	compounds	can	still	be	tested	in	flasks	and	microcentrifuge	tubes,	while	still	improving	the	time	to	completion,	simply	by	decreasing	the	amount	of	initial	parasite	required	for	each	experiment.		Since	the	primary	limiting	factor	is	parasite	growth,	decreasing	the	amount	of	culture	required	by	four-fold	would	correspondingly	lower	the	time	requirements.		With	a	smaller	amount	of	parasite	to	sample,	the	signal	output	would	also	be	decreased	substantially.		In	order	to	compensate	for	this,	the	water	additions	throughout	the	heme	fractionation	processing	steps	could	be	eliminated	as	to	not	dilute	the	absorbance	signal.		Therefore,	this	improved	method	of	target	validation	will	reduce	
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concerns	of	losing	samples	between	transfer	steps	by	eliminating	multi-channel	pipettes,	will	decrease	the	waiting	period	for	parasite	growth	to	one	week,	while	simultaneously	maintaining	signal	output	by	excluding	any	water	dilution	steps.			
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Chapter	IV	
	
REACTIVITY	AND	FORMATION	OF	THE	HEME-DRUG	COMPLEX	
	
Introduction	
Heme	species	in	solution	
Extensive	research	has	been	done	to	look	at	the	species	of	Fe(III)PPIX,	which	varies	depending	on	the	solvent	system	and	can	be	differentiated	by	their	unique	absorbance	spectra.	The	monomeric	form	of	heme	persists	in	high	concentrations	of	organic	solvent.94	Monomers	can	also	dimerize	into	either	the	µ-oxo	dimer	form,	in	which	an	oxygen	atom	bridges	the	two	iron	centers,	but	this	is	only	present	in	extremely	high	pH,	making	it	unlikely	to	be	the	species	found	in	the	parasite.		Alternatively,	dimerization	can	occur	in	the	π-π	stacked	form	where	the	hydrophobic	coplanar	unligated	faces	of	the	5-coordinate	ferriheme	species	interact.		This	can	then	become	the	µ-propionato	dimer	of	centrosymmetric	units,	which	is	thought	to	be	the	precursor	that	nucleates	Hz	formation.94			
	
Hemozoin	inhibition	mechanism		
In	vitro	studies	have	shown	quinoline	antimalarial	compounds	to	decrease	the	rate	of	β-hematin	formation.95	However,	it	was	only	within	the	last	five	years	
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that	crystallographic	information	of	the	interaction	between	antimalarials	and	heme	was	obtained.		Prior	to	this,	the	only	analysis	available	was	solution	proton	nuclear	magnetic	resonance	(NMR)	spectra	that	provided	evidence	of	a	π-π	complex	between	Fe(III)PPIX	and	CQ.96	This	was	supported	through	isothermal	titration	calorimetry	experiments,	which	suggested	a	cofacial	π-π	complex	of	CQ	with	two	eme	μ-oxo	dimers.97	Furthermore,	using	solid-state	13C	and	15N	NMR,	de	Dios	et	al.	determined	that	CQ	co-precipitates	with	Fe(III)PPIX	under	acidic	conditions	and	the	aggregates	consisted	of	covalent	CQ-Fe(III)PPIX	complexes.		This	covalent	complex	would	prevent	coordination	of	carboxylate-iron	covalent	bonds	in	the	dimeric	heme	units	and	ultimately,	hinder	formation	of	hemozoin.	
The	mechanism	of	hemozoin	formation	inhibition	by	quinoline-like	molecules	is	not	fully	understood;	however,	there	are	several	hypotheses	throughout	the	literature.		One	possible	mode	of	action	is	through	the	formation	of	a	complex	with	the	Fe(III)PPIX	dimer	prior	to	initiation	of	biomineraliziation	(Figure	18A).		CQ	binds	to	Fe(III)PPIX	monomer	with	a	dissociation	constant	between	10-7	and	10-6	M,98		indicating	high	affinity	for	and	specific	tight	association.		This	non-covalent	interaction	would	occur	immediately	following	host	hemoglobin	digestion,	yet	before	the	complex	partitions	into	the	NLDs.		If	Fe(III)PPIX	is	bound	by	CQ	molecules	through	π-π	stacking	interactions,	then	nucleation	of	the	hemozoin	crystal	cannot	occur.		While	direct	evidence	of	this	is	absent,	quinoline	molecules	have	been	found	to	significantly	increase	the	time	for	crystals	to	form,	indicating	they	may	prevent	nucleation.99	Alternatively,	CQ	may	be	interacting	with	Fe(III)PPIX	within	the	NLDs,	after	hemozoin	formation	has	already	been	initiated	(Figure	18B).		
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In	this	case,	CQ	would	cap	the	end	of	the	hemozoin	crystal,	preventing	additional	heme	units	from	extending	growth.		A	theoretical	model	of	the	interaction	of	hemozoin	and	quinolines	demonstrates	the	ability	of	the	protonated	drug	to	noncovalently	bind	to	the	fast-growing	face	of	the	crystal,	but	has	yet	to	be	confirmed.100,	101	Even	if	a	mechanism	is	established	for	one	hemozoin	inhibitor,	it	may	not	coincide	with	every	compound	known	to	target	this	pathway.		Consequently,	further	studies	are	required	to	provide	more	insight	into	the	specific	mechanisms	of	action	of	novel	hemozoin	inhibitors.		
Figure	18	The	proposed	mechanisms	of	hemozoin	formation	inhibition	by	antimalarial	compounds.	Hemozoin	inhibitors	can	either	bind	to	heme	dimers,	preventing	crystal	nucleation	(A)	or	bind	to	the	fast-growing	face	of	the	hemozoin	crystal	to	counteract	further	growth	(B).		
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Experimental	Methods	
Time	dependent	study	of	heme	speciation	
	 As	previously	described,	the	heme	speciation	and	heme	fractionation	assays	were	used	to	determine	the	ratio	of	free	heme	to	hemozoin	in	a	parasite	following	drug	treatment.		These	methods	were	used	unmodified	as	described	in	Chapter	III,	with	the	addition	of	three	time	points	throughout	parasite	growth.		With	time	zero	
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Figure	19	Compound	microscope	images	of	Giemsa-stained	Plasmodium	falciparum	at	various	stages	of	the	intraerythrocytic	life	cycle.		Images	were	obtained	using	a	100x	oil	objective	lens.		
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indicating	reinvasion	of	the	merozoite	into	a	new	erythrocyte,	antimalarial	compounds	were	administered	at	hour	8	of	the	parasite	life	cycle,	which	corresponds	to	the	early	ring	stage	(Figure	19).	Every	eight	hours,	a	sample		corresponding	to	0.25	mL	packed	cell	volume	was	removed	and	analyzed	through	the	heme	fractionation	assay.		Concurrently,	the	parasite	survivability	was	measured	by	nucleic	acid	fluorescence	after	the	addition	of	SYBR	Green-I	and	lysis	buffer.			
	
Antimalarial	stage	specificity	determination	
	 A	parasite	culture	was	synchronized	through	selectively	lysing	late	trophozoites	and	schizonts	with	sorbitol.	In	order	to	obtain	tight	synchronization	within	a	six	to	eight	hour	time	span	between	parasites,	a	second	sorbitol	treatment	was	administered	eight	hours	after	the	first.		At	around	hour	6-8	of	the	parasite	life	cycle,	each	drug	was	added	at	1	and	2	times	its	reported	IC50	value	and	allowed	to	incubate	for	four	hours.		Cultures	were	then	washed	twice	to	remove	any	remaining	drug	in	solution	and	resuspended	in	complete	media	for	continued	parasite	growth	observations.		At	various	time	points,	a	0.2	mL	sample	of	culture	was	removed	for	SYBR	Green-I	nucleic	acid	determination.		A	similar	method	was	set	up	for	the	late	stage	of	the	parasite	life	cycle.		Cultures	were	tightly	synchronized	at	the	ring	stage	and	then	allowed	to	mature	to	the	early	trophozoite	stage	prior	to	drug	treatment.			
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Heme-drug	binding	interactions	
	 Association	of	drug	compounds	to	various	species	of	heme	was	performed	with	modifications	to	a	method	previously	published	by	our	collaborators	at	the	University	of	Cape	Town.102	A	stock	solution	of	2	mM	hematin	in	the	form	of	the	µ-propionato	dimer	was	prepared	by	dissolving	hemin	chloride	in	DMSO,	made	fresh	each	day	and	stored	in	the	dark.	A	working	solution	of	10	µM	hematin	was	prepared	fresh	for	each	experiment	in	the	solvent	system	of	40%	DMSO	and	0.02	M	HEPES	(pH	7.4).		Most	drug	compounds	were	prepared	at	1	mM	in	the	solvent	system	and	sonicated/heated	to	ensure	complete	dissolution.		PYR	was	dissolved	in	ethanol	prior	to	diluting	to	1	mM	in	the	solvent	system	due	to	solubility	properties.		
	 In	a	96-well	clear,	flat-bottomed	plate,	triplicate	samples	were	prepared	in	addition	to	a	control	set	of	wells	with	the	titrated	drug	solutions	without	the	addition	of	hematin	to	remove	any	absorbance	observed	from	the	drug	itself.	A	serial	titration	of	the	drug	compound	was	performed	to	prepare	the	plate	prior	to	the	addition	of	the	hematin	solution	(final	concentration	of	5	µM)	or	solvent	system	(control	wells).	The	plate	was	incubated	at	room	temperature	in	the	dark	for	one	hour	and	absorbance	spectra	were	measured	from	300-	500	nm	using	a	BioTek	Synergy	H4	Hybrid	Plate	Reader.		Control	spectra	were	subtracted	from	each	replicate	to	obtain	spectra	from	heme	binding	alone	with	the	Soret	peak	maximum	observed	at	400	nm.		The	Log	K	binding	constants	were	calculated	for	each	compound	using	a	Curve	Fit	program	written	by	Dr.	David	Kuter	from	the	University	of	Cape	Town.			
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Determination	of	heme-drug	complex	stoichiometry	
	 The	method	of	continuous	variation	was	used	to	determine	the	binding	stoichiometry	of	various	drugs	and	Fe(III)PPIX.		Here,	the	total	combined	number	of	moles	of	drug	and	Fe(III)PPIX	was	kept	constant	(20	µmole)	while	varying	the	mole	fraction	of	each	component.	Individual	stock	solutions	of	2	mM	Fe(III)PPIX	and	2	mM	drug	compound	were	prepared	in	40%	DMSO,	0.2	M	HEPES	(pH	7.4).	The	volumes	of	Fe(III)PPIX	and	drug	stock	were	titrated	in	opposing	directions	in	the	same	solvent	system	to	ensure	µ-propionato	dimer	heme	speciation.103	The	final	mole	fractions	of	Fe(III)PPIX	to	drug	examined	were	1.00,	0.95,	0.90,	0.85,	0.80,	0.75,	0.70,	0.65,	0.60,	0.50,	0.40,	0.30,	0.20,	0.10,	and	0.00.	These	solutions	were	prepared	in	triplicate	in	a	96-well	clear,	v-bottom	plate,	mixed	for	15	minutes,	and	centrifuged	at	1000	g	for	5	minutes.	The	supernatant	was	carefully	transferred	to	a	96-well	clear,	flat-bottom	plate	and	the	absorbance	was	recorded	from	300-550	nm.	The	endpoint	value	of	400	nm	(the	maximum	peak	for	heme	Soret	band)	was	plotted	against	the	mole	fraction	of	Fe(III)PPIX	and	fit	with	a	linear	segmented	line	using	Prism	v5.0	to	find	the	point	of	intersection.			
	
Results	and	Discussion	
Two	classes	of	hemozoin	inhibitors	observed	
	 Upon	closer	examination	of	the	31	compounds	that	were	tested	in	the	target	validation	assay,	there	appeared	to	be	two	classes	of	hemozoin	inhibitors.		One	class,	
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including	CQ,	exhibited	a	difference	in	intracellular	free	heme	of	20-30%	between	basal	levels	without	drug	treatment	and	the	highest	“kill”	concentration	of	drug.		Alternatively,	other	hemozoin	inhibitors	exhibited	differences	in	free	heme	closer	to	60-80%.		This	observation	stimulated	questions	of	the	specific	mechanism	of	how	inhibitors	interact	with	heme	or	hemozoin	during	the	crystallization	process.	Does	this	difference	offer	an	explanation	for	how	these	compounds	are	interacting	with	heme	or	hemozoin?		Furthermore,	why	does	one	class	of	compound	result	in	such	high	intracellular	free	heme,	when	heme	toxicity	is	known	to	be	extremely	potent?		
	
Time	dependent	increase	of	free	heme	
	 The	previous	chapter	focused	on	validating	antimalarial	inhibition	of	hemozoin	formation	in	a	parasite	culture	at	a	single	stage	of	the	life	cycle,	mature	trophozoites.	To	reduce	the	chance	for	resistance,	an	effective	treatment	would	ideally	combine	two	drugs	targeting	different	life	stages.		Hemozoin	inhibitors	have	been	shown	to	target	the	ring	stage,	as	this	is	when	the	parasite	begins	to	digest	host	hemoglobin	in	order	to	obtain	nutrients	as	well	as	make	space	for	its	growth.		However,	with	variation	observed	within	the	class	of	hemozoin	inhibitors,	we	proposed	that	heme	quantification	at	various	stages	following	drug	treatment	could	determine	the	point	at	which	a	specific	drug	is	most	effective.			
	 When	CQ	was	administered	to	a	D6	parasite	culture	for	heme	fractionation	and	parasite	survivability	analysis,	we	found	that	the	drug	was	effective	within	the	first	eight	hours	of	treatment	(Figure	20A).		The	parasites	remained	in	ring	form,	
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less	likely	to	mature	into	trophozoites	as	CQ	quickly	caused	deleterious	effects	on	the	hemozoin	formation	pathway.		The	levels	of	free	heme	versus	hemozoin	remained	constant	over	the	course	of	a	single	life	cycle,	but	were	elevated	at	the	higher	doses	of	administered	drug.		This	supports	the	idea	that	CQ	is	a	fast	acting	drug	and	targets	the	early	ring	stage	of	the	life	cycle.38	
	 We	then	sought	to	use	two	examples	from	our	HTS	efforts	to	explain	why	drastically	different	heme	percentages	following	drug	treatment	were	found	between	compounds.		TCMDC-125529	resulted	in	“low”	changes	in	free	heme	percentages	(~20%)	after	a	kill	concentration	drug	treatment,	similar	to	what	was	seen	with	CQ.		The	time	study	with	collection	of	parasite	culture	every	eight	hours	also	showed	similar	results	with	free	heme	remaining	constant	over	time,	but	elevated	at	higher	doses	(Figure	20B).		Again,	this	class	of	“low”	free	heme	producing	compounds	may	be	specific	to	causing	death	early	on	in	the	parasite	life	cycle.		In	comparison,	TCMDC-124972	was	determined	to	be	a	part	of	the	“high”	free	heme	compound	class.		We	observed	a	drastic	difference	in	free	heme	percentages	at	the	trophozoite	stage	compared	to	no	drug	treatment.		However,	when	comparing	free	heme	differences	amongst	the	entire	life	cycle,	free	heme	values	at	hour	16	were	significantly	(p	<	0.01)	lower	than	those	at	the	later	life	stages	(Figure	20C).		This	gradual	increase	in	free	heme,	and	correspondingly	the	gradual	decrease	in	hemozoin,	could	indicate	that	this	compound	slows	down	the	rate	at	which	the	parasite	dies.	This	slower	rate	would	allow	for	high	accumulation	of	free	heme	in	the	parasite	before	toxicity	prevails.		However,	this	leads	us	to	the	question	of	why	these	drug	complexes	allow	for	high	concentrations	of	free	heme,	a	substance	
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known	to	be	toxic	at	extremely	low	levels.		These	results	provide	a	glimpse	towards	the	specific	ability	to	inhibit	hemozoin	formation;	however,	we	must	begin	to	look	at	the	interaction	between	the	drug	and	heme	and	the	effect	it	has	on	activity.			
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Figure	20	Heme	quantification	following	drug	treatment	throughout	a	single	parasite	life	cycle.		A	D6	parasite	culture	was	treated	with	CQ	(A),	TCMDC-125529	(B),	and	TCMDC-124972	to	observe	any	variation	in	the	speciation	of	heme	at	different	life	stages.		Black	bars	represent	the	amount	of	free	heme	(left	graphs)	and	hemozoin	(right	graphs)	of	control	cultures	without	drug	treatment	(left	axes).		The	curves	represent	parasite	survival	at	each	time	point	according	to	SYBR	Green-I	fluorescence	(right	axes).			
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Stage	specificity	determination	
	 To	further	corroborate	the	life	cycle	stage	that	these	antimalarial	compounds	target,	drug	treatment	was	administered	to	tightly	synchronized	ring	stage	and	trophozoite	stage	parasites,	separately.		Following	CQ	treatment,	the	early	stage	culture	was	unable	to	recover	as	seen	with	constant	SYBR	Green-I	fluorescence	(Figure	21A).		CQ	prevented	parasite	growth	at	the	early	ring	stage	as	maturation	and	reinvasion	of	new	merozoites	never	occurred;	however,	treatment	at	the	later	stages	did	not	affect	parasite	survival	(Figure	21B).		Similarly,	the	compounds	TCMDC-125529	and	TCMDC-124972	also	prohibited	mature	parasites	from	forming,	targeting	the	early	ring	stage	of	the	life	cycle,	but	at	a	lesser	ability	than	with	CQ.	In	contrast,	PYR	administration	at	the	early	ring	stage	had	no	effect	on	parasite	maturation	and	reinvasion,	but	instead	acted	at	the	trophozoite	stage	(Figure	21B).	These	two	classes	of	compounds	inhibit	both	hemozoin	formation	and	specifically	the	ring	stage	of	the	parasite	life	cycle.		From	these	results,	we	were	unable	to	determine	the	exact	hour	of	highest	efficacy	for	each	compound.		Additional	time	points	must	be	added	for	a	more	precise	measurement.		Furthermore,	the	question	of	why	these	compounds	act	differently	still	remains.			
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Figure	21	A	D6	culture	of	tightly	synchronized	ring	stage	(A)	or	late	stage	(B)	parasites	were	treated	with	four	antimalarial	compounds	at	the	IC50	value	previously	determined	for	each	compound.	SYBR	Green-I	fluorescence	was	measured	to	determine	the	percent	survival	after	4,	12,	and	24-hour	incubation.		Three	individual	samples	were	averaged	with	standard	deviations	reported.					
Determination	of	heme-drug	binding	constant	
	 In	order	for	hemozoin	inhibition	to	occur,	the	antimalarial	compounds	must	interact	with	either	the	hemozoin	crystal	or	free	heme	in	solution.	Therefore,	we	observed	the	heme-drug	complexes	that	form	using	the	absorbance	properties	of	heme.	Compound	interaction	with	the	µ-propionato	heme	dimer	was	measured	following	drug	titration	with	a	5	µM	heme	solution	in	40%	DMSO,	pH	7.4	in	order	to	mimic	the	heme	species	most	likely	to	be	the	precursor	for	the	hemozoin	crystal.		When	the	Soret	maximum	absorbance	peak	decreases	with	increasing	drug	concentration,	the	compound	must	be	interacting	with	Fe(III)PPIX.	This	decrease	can	then	be	used	to	calculate	Log	K,	the	binding	constant	of	each	compound	relative	to	the	µ-propionato	heme	dimer.			
	 The	four	known	antimalarial	compounds	were	tested	here	to	first	validate	our	methods.		When	CQ	was	titrated	with	a	standard	heme	solution,	a	decrease	in	absorbance	was	found	at	400	nm	(Figure	22A).		However,	no	changes	in	absorbance	was	observed	with	PYR	or	ATV,	which	there	is	no	evidence	of	heme	binding	required	for	antimalarial	activity	reported.104	The	role	of	heme	in	ART	activity	is	still	
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highly	debated.105	Here,	ART	did	not	interact	with	the	µ-propionato	dimer	form	of	heme,	at	least	in	a	manner	that	affects	the	Soret	band,	which	supports	the	hypothesis	of	a	heme-independent	activation	of	ART.106	However,	since	the	Soret	peak	is	present	in	the	absence	of	iron,	one	possible	explanation	is	that	ART	activity	is	still	heme-dependent,	but	only	through	interaction	with	iron,	not	affecting	the	porphyrin	ring.107	
The	two	exemplary	compounds	from	our	HTS	efforts	were	also	mixed	with	heme	in	order	to	further	validate	them	as	active	hemozoin	inhibitors	through	binding	effects.			The	“low”	free	heme	class	example,	TCMDC-125529,	surprisingly	did	not	bind	to	the	µ-propionato	dimer	form	of	heme	as	tightly	as	its	similar	CQ	counterpart	(Figure	22B).		This	lack	of	interaction	observed	through	Soret	band	decline	may	simply	indicate	that	this	compound	functions	through	capping	the	fast	growing	face	of	the	hemozoin	crystal.		This	supports	our	HSA	results	of	“low”	free	heme	levels	following	drug	treatment	as	most	of	the	heme	is	already	bound	up	in	the	crystal	form	before	the	parasite	dies	from	small	amounts	of	toxic	free	heme	in	solution.		TCMDC-124972	resulted	in	tight	binding	with	the	µ-propionato	dimer	form	of	heme	upon	drug	titration	(Figure	22B).	This	agrees	with	our	HSA	results	and	hypothesis	that	this	compound	binds	to	the	dimeric	form	prior	to	nucleation	and	interaction	with	the	NLDs,	causing	high	levels	of	free	heme	to	remain	in	solution	compared	to	being	bound	up	in	crystal	form.		In	order	to	observe	where	these	drugs	interact	with	heme	in	relation	to	the	NLDs	requires	localization	studies.			
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Figure	22	Antimalarial	compound	titration	with	5	µM	hematin	in	the	form	of	the	µ-propionato	dimer.		The	maximum	absorbance	value	from	the	Soret	band	at	400	nm	was	recorded	for	triplicate	samples.		CQ	interaction	with	the	µ-propionato	dimer	decreases	absorbance	as	the	Soret	peak	is	abrogated,	while	ART,	PYR,	and	ATV	curves	indicate	a	lack	of	drug-dimer	interaction	(A).	TCMDC-125529	did	not	result	in	strong	binding	with	the	µ-propionato	dimer	form	of	heme,	as	opposed	to	CQ	and	TCMDC-124972	(B).			
Determination	of	heme-drug	complex	stoichiometry	
The	method	of	continuous	variation	was	used	to	determine	the	heme-drug	complex	stoichiometry,	utilizing	the	signature	Soret	band	of	the	porphyrin	rings	of	hemek.	As	previously	shown,	the	binding	stoichiometry	for	a	mixture	of	hematin	and	CQ	corresponded	to	two	equivalents	of	Fe(III)PPIX	for	every	one	CQ	molecule,	indicating	that	the	heme	is	in	a	dimeric	form102	(Figure	23).	In	comparison,	PYR	was	confirmed	to	not	bind	to	heme	as	the	Soret	peak	increased	linearly	with	greater	heme	mole	fractions.		ART	and	ATV	both	found	to	have	1:1	stoichiometric	relationships	with	heme,	which	has	been	previously	suggested	in	the	literature;104,	
108	however,	the	exact	orientation	of	binding	cannot	be	determined	from	this.			With	our	results	being	supported	in	the	literature	for	known	antimalarials,	we	turned	to	determining	the	stoichiometric	relationships	between	heme	and	examples	of	the	GSK	hemozoin	inhibitors.	The	two	exemplary	hit	compounds	from	the	different	classes	of	hemozoin	inhibitors	were	mixed	with	heme	at	varying	mole	fractions.		TCMDC-125529	did	not	associate	with	Fe(III)PPIX	in	a	manner	that	altered	the	
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Soret	absorbance	pattern	of	heme,	as	observed	previously.	On	the	other	hand,	TCMDC-124972	showed	baseline	absorbance	values	until	the	1:1	stoichiometric	Fe(III)PPIX	to	compound	ratio	(Figure	23).		Therefore,	this	compound	is	able	to	bind	to	both	faces	of	the	heme	dimer	suggesting	that	a	drug-dimer	complex	could	be	forming,	not	allowing	any	signal.	Once	the	amount	of	heme	exceeded	the	amount	of	TCMDC-124972	in	solution,	then	an	increase	in	Soret	absorbance	is	observed.		This	complete	complexation	could	subsequently	explain	the	high	levels	of	free	heme	observed	prior	to	parasite	death	as	the	heme	iron	center	is	blocked	from	undergoing	Fenton	Chemistry	reactions,	producing	reactive	oxygen	species,	and	consequently,	having	minimal	toxic	effects.			
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Figure	23	The	method	of	continuous	variation	was	used	to	determine	stoichiometry	of	the	antimalarial	compounds	to	the	µ-propionato	dimer	form	of	heme	in	40%	DMSO,	pH	7.4.		A	segmented	linear	regression	line	was	plotted	along	with	the	average	and	standard	deviation	from	three	replicates	of	the	absorbance	observed	from	heme	in	solution.		TCMDC-125529	did	not	bind	heme,	as	previously	shown.		CQ	and	TCMDC-124972	resulted	in	two	segmented	lines	with	the	point	of	intersection	indicating	the	stoichiometric	relationship	between	drug	and	heme.					
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Conclusions	and	Future	Directions	
While	a	great	deal	of	knowledge	regarding	current	antimalarial	drugs	has	been	uncovered,	definitive	evidence	concerning	the	exact	modes	of	action	has	yet	to	be	determined.	Determining	stage	specificity	of	antimalarial	compounds	provided	evidence	for	the	two	classes	of	compounds	that	were	observed	in	our	HSA.		Furthermore,	the	extent	of	heme-drug	complexes	that	form	can	provide	us	with	a	more	detailed	explanation	for	why	these	two	classes	vary	in	nature.		Even	still,	it	is	vague	as	to	whether	each	compound	within	the	class	of	hemozoin	inhibitors	function	through	identical	mechanisms.		A	more	thorough	study	of	the	specific	compound	properties	can	be	done	through	structure	activity	relationships	of	a	few	scaffolds	to	determine	the	most	efficacious	properties	for	the	specific	application.		
Discovering	the	precise	location	within	the	digestive	vacuole	of	hemozoin	inhibition	could	indicate	whether	the	drug	binds	to	intracellular	free	heme	or	a	growing	crystal.		One	method	to	do	this	is	through	permeability	studies	across	an	artificial	membrane.		If	the	drug	compounds	are	able	to	pass	through	a	phospholipid	membrane	mimicking	the	digestive	vacuole	membrane	and	partition	into	an	acidic	environment,	they	should	be	able	to	localize	in	the	area	of	hemozoin	formation.		Furthermore,	we	could	observe	permeability	in	the	presence	of	NLDs	to	uncover	more	specific	localization	information.		An	alternative	method	for	determining	localization	of	drug	activity	is	through	the	use	of	fluorescent	probes.		
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Chapter	V	
	
DETERMINING	DRUG-HEME	INTERACTIONS	USING	FLUORESCENT	PROBES	
	
Introduction	
Eukaryotic	organisms	use	lipids	as	storage	compartments,	a	source	of	energy,	and	in	membrane	synthesis;109	however,	P.	falciparum	lacks	the	ability	to	oxidize	lipids	for	energy,27	which	poses	the	question	as	to	the	role	of	neutral	lipids	in	the	parasite.		NLDs	are	found	within	the	digestive	vacuole	of	the	malaria	parasite	and	are	involved	in	the	mediation	of	hemozoin	formation.	As	the	parasite	grows,	the	relative	abundance	of	lipid	bodies	increases,54	which	correlates	to	hemozoin	formation	throughout	the	life	cycle.		
Previously,	nile	red,	a	lipid-specific	fluorescent	probe,	has	been	shown	to	uniformly	label	synthetic	NLDs	used	as	a	mimic	for	the	lipid	droplets	of	the	malaria	parasite.54	When	Fe(III)PPIIX	was	introduced	into	this	system,	nile	red	fluorescence	was	completely	quenched	within	150	seconds	observed	by	confocal	microscopy,	but	only	in	a	pH	environment	between	2.3	and	5.5.		This	was	the	first	visual	demonstration	that	Fe(III)PPIX	quickly	accumulates	in	lipophilic	environments,	yet	is	pH	dependent	due	to	the	overall	charge	on	heme.		In	addition	to	the	lipid	requirement	for	hemozoin	formation,	antimalarial	drug	compounds	have	also	been	shown	to	interact	with	the	NLDs	to	prevent	this	detoxification	process.		One	
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proposed	mechanism	includes	heme-drug	complexes	entering	this	lipid	environment	and	preventing	nucleation.26	Alternatively,	Sullivan	et	al.	demonstrated	CQ	and	quinidine	binding	to	hemozoin	in	parasites,	but	still	required	the	presence	of	free	heme.110		
Additional	studies	used	fluorescent	probes	with	antimalarial	compounds	as	a	way	to	determine	localization	and	mechanism	of	drug	metabolites	in	P.	falciparum.	Hartwig	et	al.	synthesized	fluorescently	tagged	ART	derivatives	that	were	found	to	accumulate	in	the	parasite	digestive	vacuole	and	only	have	activity	in	the	presence	of	heme.111	Recently,	CQ	fluorescently	labeled	with	BODIPY-FL	was	also	shown	to	localize	within	the	digestive	vacuole	of	P.	falciparum.112,	113	However,	we	propose	that	this	fluorescent	CQ	can	more	specifically	be	found	associated	with	the	NLDs	of	the	digestive	vacuole,	the	location	of	hemozoin	formation	and	CQ	activity.63	Here,	we	discuss	the	use	of	fluorescent	probes	to	determine	the	subcellular	localization	of	CQ	and	its	interaction	with	both	NLDs	and	Fe(III)PPIX.		
	
	 	 Experimental	Methods	
Materials	
The	following	lipids	were	obtained	from	Nu-Check	Prep,	Inc.	(Elysian,	MN):	monostearoylglycerol	(MSG),	monopalmitoylglycerol	(MPG),	1,3-dilineoleoylglycerol	(DLG),	1,3-dioleoylglycerol	(DOG),	and	1,3-dipalmitoylglycerol	(DPG).		Green	fluorescent	chloroquine	(gfCQ)	tagged	with	BODIPY-FL	was	
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purchased	through	BioLynx	Technologies	Pte.	Ltd	(Singapore).	Nile	red	(9-diethylamino-5H-benzo[a]phenoxazine-5-one)	and	hemin	chloride	were	obtained	from	MP	Biomedicals,	LLC.		The	fluorescent	dyes,	SYTO	61	and	5-(and	6-)	chloromethyl-2',7'-dichlorodihydrofluorescein	diacetate		(CM-H2DCFDA)	were	purchased	from	Thermo	Fisher	Scientific.	
	
Preparing	synthetic	neutral	lipid	droplets	
A	2	mM	stock	solution	of	the	lipid	blend	at	the	previously	described	ratio	of	4:2:1:1:1	MSG:MPG:DLG:DOG:DPG	was	prepared	in	a	9:1	methanol/acetone	mixture	to	promote	solubility	and	warmed	to	37°C.		A	50	mM	citrate	buffer	(pH	4.8)	was	equilibrated	in	a	37°C	water	bath	for	15	minutes.		A	sample	of	lipid	blend	stock	(200	μL)	was	gently	deposited	drop-wise	on	top	of	the	citrate	buffer	solution	using	a	27G	x	½	(0.4	mm	x	13	mm)	needle	and	allowed	to	equilibrate.	Once	the	synthetic	NLDs	had	spontaneously	formed,	they	were	extracted	using	a	20G	x	1.5-inch	needle,	making	sure	to	remove	only	the	bulk	lipid	sub	phase,	while	avoiding	the	surface	lipid	monolayer,	to	obtain	a	lipid	emulsion.		
	
Fluorescent	labeling	of	synthetic	neutral	lipid	droplets	
	 Synthetic	NLDs	were	labeled	with	nile	red	(3	μM	final	concentration)	and/or	gfCQ	(0.5	μM	final	concentration)	by	first	mixing	the	fluorescent	probe	with	the	lipid	emulsion	(300	μM	final	concentration)	before	diluting	to	1	mL	with	citrate	buffer	
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(50	mM,	pH	4.8).	Quenching	studies	were	conducted	with	hemin	chloride	suspended	in	DMSO	and	added	to	the	fluorescently	labeled	synthetic	NLDs.		The	fluorescence	signal	was	measured	on	a	BioTek	Synergy	H4	Plate	Reader.		Nile	red	was	excited	at	530	nm	and	exhibited	an	emission	maximum	around	650	nm,	while	gfCQ	was	excited	at	480	nm	and	had	an	emission	maximum	peak	of	520	nm.			
	
Confocal	microscopy	of	labeled	synthetic	neutral	lipid	droplets	
Following	one	hour	incubation,	the	fluorescently	labeled	synthetic	NLD	solution	was	transferred	to	a	glass	bottom	microwell	dish	(MatTek	Corporation,	35mm,	No.	0,	uncoated)	for	imaging	using	a	Zeiss	LSM	510	META	inverted	confocal	microscope	or	an	Olympus	FV-1000	inverted	confocal	microscope	each	with	a	100x	oil	objective	lens.		Nile	red	was	imaged	using	a	543	nm	HeNe	laser	with	a	Rhodamine	emission	filter.		A	488	nm	argon	laser	with	a	FITC	emission	filter	was	used	to	image	the	gfCQ	samples.	Differential	interference	contrast	(DIC)	images	and	3-D	z-stack	images	were	recorded	for	all	samples.	
	
Confocal	microscopy	of	fluorescently	labeled	parasite	culture	
	 A	D6	culture	of	5-10%	parasitemia,	consisting	of	more	than	90%	trophozoites,	was	incubated	with	gfCQ	(2	μM)	for	four	hours.		Following	two	washes	with	PBS,	the	culture	was	resuspended	at	5%	hematocrit	with	phenol	red	free	complete	media	and	deposited	in	a	35mm	glass	bottom,	uncoated	MatTek	dish	for	
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imaging.		Samples	were	viewed	with	100x	oil-immersion	on	an	Olympus	FV-1000	confocal	microscope.	DIC	images	were	overlaid	with	the	fluorescence	observed	and	z-stacks	were	obtained	to	confirm	incorporation	of	the	compound	in	the	parasite.	Similar	experiments	were	done	using	a	CQ-resistant	strain,	C235	with	microscope	parameters	constant	for	all	experiments	in	order	to	directly	compare	fluorescence	intensity.		
	
Observation	of	reactive	oxygen	species		
	 A	culture	of	ring	stage	parasites	(D6)	at	5-10%	parasitemia	and	2%	hematocrit	was	incubated	with	four	antimalarial	compounds	at	their	previously	determined	IC50	in	a	24-well	clear,	flat-bottomed	cell	culture	plate.		After	10	hours	at	37°C	in	5%	CO2,	5%	O2,	90%	N2,	SYTO	61,	a	nucleic	acid	stain,	was	added	to	each	well	(0.5	µM	final	concentration)	and	mixed	thoroughly.		Fifteen	minutes	later,	the	general	oxidative	stress	indicator,	CM-H2DCFDA,	was	introduced	at	a	concentration	of	5	µM.		After	30	additional	minutes,	each	sample	was	washed	twice	with	PBS	and	deposited	on	an	ibidi	8-well	collagen	IV-coated	µ-slide	at	0.05%	hematocrit.		Samples	were	immediately	imaged	on	an	Olympus	FV-1000	confocal	microscope	with	a	100x	oil	objective	lens.		SYTO	61	utilized	a	HeNe	633	nm	laser	and	AlexaFluor	633	emission	filter,	while	CM-H2DCFDA	was	excited	by	an	argon	488	nm	laser	and	collected	using	the	FITC	filter.		The	following	parameters	were	used	for	all	experiments:	488	nm	laser	(6%),	amplifier	offset:	9%,	600	V,	and	amplifier	gain:	1;	
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633	nm	laser	(5%),	amplifier	offset:	5%,	235	V,	and	amplifier	gain:	1;	and	pinhole:	195	µm.			
Results	and	Discussion	
Interaction	between	chloroquine	and	neutral	lipid	droplets	
	 As	previously	shown,	CQ	binds	to	the	heme	dimer	in	a	1:2	ratio;	however,	CQ	interactions	with	synthetic	NLDs	have	never	previously	been	explored.	By	using	unlabeled	CQ	and	nile	red	we	were	able	to	explore	this	interaction	and	also	probe	the	location	within	the	parasite	that	CQ	binds	to	heme.		A	300	µM	NLD	solution	in	citrate	buffer	(50	mM,	pH	4.8)	was	labeled	with	nile	red	at	varying	concentrations	and	the	fluorescence	was	measured	on	a	BioTek	Synergy	H4	plate	reader.		From	this,	the	labeling	capacity	within	the	linear	range	was	determine	to	be	3	µM	and	was	used	as	the	final	concentration	for	all	subsequent	experiments.		As	previously	reported	in	our	lab,	heme	quenched	nile	red	fluorescence	through	π-π	interactions	indicating	the	rapid	partitioning	of	the	porphyrin-containing	molecule	into	the	NLDs.54	Similarly,	a	CQ	solution	in	citrate	buffer	was	titrated	into	the	nile	red	labeled	NLD	solution,	but	unlike	hemin,	this	fluorescence	remained	constant	even	up	to	500	µM	CQ.	Since	CQ	did	not	cause	a	change	in	nile	red	fluorescence	within	the	NLDs	one	may	conclude	that	the	drug	is	not	partitioning	into	the	lipids	in	order	to	interact	with	the	nile	red.		However,	when	CQ	was	titrated	into	a	nile	red	solution	in	acetone	in	the	absence	of	lipids,	the	fluorescence	remains	unchanged.	This	lack	of	quenching	indicates	that	the	CQ	compound	alone	is	unable	to	interact	with	nile	red	in	a	way	that	alters	its	fluorescence	signal.		Therefore,	we	are	unable	to	determine	if	CQ	
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partitions	into	the	NLDs	from	these	observations	and	required	an	alternative	strategy	to	ascertain	CQ	localization.				
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Figure	24	Structure	of	commercially	available	chloroquine-BODIPY-FL,	referred	to	in	the	text	as	green	fluorescent	chloroquine.		
	
Chloroquine	interaction	with	heme	in	the	neutral	lipid	droplets	
CQ	conjugated	to	a	BODIPY-FL	moiety	(Figure	24)	was	purchased	to	help	visually	ascertain	the	destination	of	this	antimalarial	compound.		NLDs	were	labeled	with	gfCQ,	in	citrate	buffer	while	hemin	was	subsequently	titrated	into	the	solution,	
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Figure	25	Stern-Volmer	relationship	between	the	lipophilic	fluorophore,	nile	red,	and	the	fluorescent	antimalarial,	CQ,	in	the	presence	of	NLDs	following	titration	with	hemin	as	a	fluorescent	quencher.		The	slope	of	the	line	indicates	the	ability	of	heme	to	quench	the	fluorescence.		Graphs	represent	the	average	and	standard	deviation	of	three	samples,	fit	with	a	linear	regression	line.		
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resulting	in	quenching	of	fluorescence	similar	to	that	previously	observed	with	nile	red.		Since	heme	is	known	to	partition	into	NLDs,	it	can	be	used	as	the	quencher	for	both	nile	red	and	gfCQ	fluorescent	probes.	The	collisional	quenching	of	the	excited	fluorophores	by	heme	was	calculated	using	the	Stern-Volmer	relationship	(Equation	1),	where	I0	is	the	intensity	at	λmax	without	quencher,	I	is	the	intensity	at	λmax	in	the	presence	of	quencher,	KSV	is	the	Stern-Volmer	quencher	constant,	and	[Q]	is	the	concentration	of	the	quencher.		This	relationship	was	plotted	with	the	quencher	concentration	(hemin)	as	the	abscissa	and	the	ratio	of	emission	intensity	without	quencher	to	the	presence	of	quencher	(I0	/	I)	at	that	specific	concentration	on	the	ordinate	(Figure	25).		The	smaller	slope	of	0.053	±	0.005	observed	with	nile	red	compared	to	gfCQ	(m=	0.100	±	0.007)	indicates	the	increased	difficulty	for	the	quencher	(heme)	to	reach	the	fluorophore	inside	of	the	NLD.		This	provides	further	evidence	that	gfCQ	is	free	in	solution	or	on	the	surface	of	the	lipids,	but	still	does	not	specify	any	interaction	with	the	NLDs.114	If	gfCQ	molecules	were	preferentially	found	within	the	NLD,	like	with	nile	red,	then	a	similar	slope	would	have	been	observed	following	the	titration	of	heme.		However,	since	gfCQ	is	capable	of	fluorescing	in	both	aqueous	and	lipophilic	environments,	then	we	must	use	an	alternative	method	to	determine	if	this	probe	is	able	to	partition	into	the	synthetic	NLDs	or	if	it	simply	resides	on	the	exterior.		
	
Equation	1	
	
!!! = 1+  !!" ! 	
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Similar	to	the	parallax	method,115	the	location	of	gfCQ	relative	to	synthetic	NLDs	was	determined	by	contrasting	the	amount	of	fluorescent	quenching	in	solutions	with	and	without	synthetic	NLDs	present.	In	the	absence	of	synthetic	NLDs,	heme	more	easily	quenched	the	gfCQ	fluorescence	than	a	solution	with	gfCQ	preincubated	with	NLDs	(Figure	26).		Furthermore,	the	intensity	increases	with	a	sharp	slope	at	lower	quencher	concentrations	without	NLDs	present,	indicating	the	NLDs	are	acting	as	a	barrier	or	obstacle	for	the	heme	to	overcome	before	it	can	interact	with	the	gfCQ.		The	difference	in	Stern-Volmer	equations	observed	between	solutions	indicates	that	gfCQ	partitions	into	the	NLDs.		If	the	gfCQ	were	only	in	the	buffer	and	not	inside	of	the	NLDs,	then	the	two	curves	would	be	more	similar	in	shape.		Instead,	with	the	gfCQ	found	within	the	NLDs,	a	barrier	lies	between	the	fluorescent	dye	and	the	quencher,	requiring	a	higher	quencher	concentration	before	it	is	able	to	pass	through	the	lipids	and	reach	the	dye.		This	data	supports	our	previous	findings	from	the	heme	speciation	assay,	which	described	CQ	partitioning	into	the	NLDs	to	prevent	hemozoin	formation	through	capping	the	fast	growing	face	of	the	crystal.		It	also	supports	the	idea	that	CQ-heme	complexes	are	able	to	partition	into	NLDs	to	prevent	hemozoin	formation.116	Since	we	have	observed	that	all	hemozoin	inhibitors	do	not	have	identical	mechanisms	of	action,	the	use	of	fluorescently	labeled	compounds	can	help	provide	more	evidence	as	to	the	localization	of	inhibition	for	specific	antimalarial	compounds.			
		 90	
	
Visualization	of	fluorophore	location	within	synthetic	neutral	lipid	droplets	
	 	To	directly	visualize	the	location	of	these	two	fluorescent	probes,	a	solution	of	synthetic	NLDs	in	PBS	was	imaged	by	confocal	microscopy.	A	2	mM	lipid	blend	stock	solution	was	incubated	with	nile	red	prior	to	the	addition	citrate	buffer,	which	allowed	the	formation	of	NLDs	as	previously	described.54	This	solution	was	placed	on	a	glass	microwell	dish	and	the	lipids	were	allowed	to	settle	before	imaging.		Nile	red	labeling	of	the	synthetic	NLDs	was	observed	with	minimal	background	fluorescence	(Figure	27A).		In	another	sample,	gfCQ	was	mixed	with	the	lipid	blend	solution	prior	to	nile	red	addition,	followed	by	citrate	buffer	to	form	the	synthetic	NLDs.	Nile	red	labeling	was	used	to	determine	lipid	droplet	location	as	it	has	
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Figure	26	Fluorescence	of	3	µM	green	fluorescent	chloroquine	in	citrate	buffer,	pH	4.8	in	the	absence	(open	circles,	dotted	line)	and	presence	of	synthetic	NLDs	(closed	circles,	solid	line)	following	the	addition	of	hemin.	The	average	and	standard	deviation	of	triplicate	samples	are	reported.	Y-axis	values	indicate	the	ratio	between	fluorescent	intensity	of	gfCQ	without	heme	quencher	and	the	fluorescent	intensity	at	the	given	concentration	of	heme.		
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minimal	fluorescence	signal	in	aqueous	solutions.		The	colocalization	of	gfCQ	and	nile	red	was	observed	throughout	the	synthetic	NLDs	using	focal	z-stack	images	(Figure	27B).		Background	fluorescence	was	prevalent	with	the	gfCQ	due	fluorescence	in	both	aqueous	and	lipophilic	environments,	but	the	gfCQ	was	found	to	concentrate	within	the	NLDs	with	greater	signal	intensity.		Again,	this	supported	the	hypothesis	of	CQ	interaction	with	NLDs,	the	site	of	hemozoin	formation.		
	
	
Figure	27	Confocal	microscopy	images	of	synthetic	NLDs	labeled	with	3	µM	nile	red		(A)	or	colabeled	with	3	µM	nile	red	and	500	nM	gfCQ	(B).	The	z-plane	images	indicate	fluorescence	is	present	throughout	the	entire	lipid	droplet	with	signal	intensity	along	the	yellow	lines	shown	by	the	line	plots.		
Visualization	of	fluorophore	location	within	Plasmodium	falciparum	
	 Once	the	fluorophore	interaction	with	synthetic	NLDs	was	established	with	confocal	microscopy,	a	culture	of	P.	falciparum	was	then	subjected	to	the	probes	to	observe	biological	localization.		A	parasite	culture	(5%	parasitemia,	2%	hematocrit)	
B A 
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was	incubated	with	nile	red	and	gfCQ	for	four	hours	and	then	washed	from	any	excess	dye.	The	resulting	images	showed	that	nile	red	was	found	in	punctate	spots	closely	associated	with	the	digestive	food	vacuole	and	gfCQ	was	delocalized	within	the	entire	parasite	cytosol	(Figure	28A).		This	observation	provides	further	evidence	of	CQ	complexation	with	heme	in	an	aqueous	environment	prior	to	interaction	with	the	NLDs.116	Furthermore,	we	contrasted	the	fluorescence	of	gfCQ	between	a	CQ	sensitive	(D6)	and	CQ	resistant	(C235)	strain	of	P.	falciparum	(Figure	28B	and	C).		Images	were	obtained	using	identical	intensity	parameters	showed	that	the	CQ	resistant	strains	overall	had	a	lower	fluorescence	due	to	the	decreased	uptake	of	drug.117			
	
Reactive	oxygen	species	production	as	a	result	of	drug	treatment	
	 In	addition	to	localization	studies,	we	used	fluorescent	probes	as	a	method	to	understand	the	biological	differences	between	the	two	classes	of	compounds	determined	from	the	heme	speciation	assay	results	that	showed	“low”	free	heme	
Figure	28	Confocal	image	of	D6	strain	of	P.	falciparum	incubated	simultaneously	with	nile	red	and	gfCQ.	Colocalization	was	observed,	but	nile	red	was	confined	to	a	smaller	area	of	the	parasite,	most	likely	the	NLDs.		Confocal	images	of	CQ	sensitive	(B)	and	multidrug	resistant	(C)	P.	falciparum	following	a	four	hour	incubation	with	fluorescent	CQ.	Fluorescent	intensity	is	increased	in	the	D6	strain	compared	to	C235.	Z-plane	sections	are	shown	on	the	bottom	and	right	of	images.			
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accumulation	versus	“high”	free	heme	accumulation	prior	to	death.	Following	drug	treatment,	the	presence	of	reactive	oxygen	species	(ROS)	was	observed	using	confocal	microscopy.		The	general	oxidative	stress	indicator,	CM-H2DCFDA,	enters	cells	through	passive	diffusion	and	parasite	esterases	cleave	the	acetate	groups	while	glutathione	reacts	with	the	thiol-reactive	chloromethyl	group.118	Various	ROS,	including	H2O2	and	O2-,	then	oxidizes	this	charged	molecule	and	subsequently	becomes	fluorescent.		Following	treatment	with	a	hemozoin	inhibitor,	toxic	free	heme	accumulates	in	the	parasite,	which	is	capable	of	forming	ROS.			
We	visually	observed	this	ROS	accumulation	following	treatment	at	the	IC50	using	CM-H2DCFDA	and	identical	parameters	on	the	confocal	microscope	(Figure	29).	Control	cultures	without	drug	treatment,	had	minimal	ROS	present,	but	showed	strong	nucleic	acid	fluorescence	in	the	parasitized	red	blood	cells.	PYR	was	used	as	a	negative	control	as	it	inhibits	a	biological	pathway	that	induces	lipid	peroxidation,119	which	is	not	measurable	by	CM-H2DCFDA120	and	exhibited	similar	fluorescence	signal	to	the	control	cultures.		When	CQ	was	incubated	with	a	parasite	culture,	the	amount	of	ROS	present	was	drastically	increased,	as	indicated	by	the	line	signal	intensity,	corresponding	to	heme	toxicity.		This	fluorescent	signal	was	observed	throughout	the	entire	parasite,	as	observed	through	z-stack	images,	and	correlated	well	with	the	nucleic	acid	stain,	indicating	parasite	location	within	erythrocytes.			
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Figure	29	Confocal	microscopy	images	of	a	D6	culture	of	P.	falciparum	to	demonstrate	the	production	of	ROS	following	drug	treatment	at	the	IC50.		Control	cultures	without	drug	treatment	(A)	and	negative	control	drug	treatment	with	PYR	(B)	only	exhibited	SYTO	61	expression	(red),	which	corresponds	to	nucleic	acids	present	in	parasites,	not	in	mature	red	blood	cells.		The	positive	control	drug	treatment,	CQ	(C),	resulted	in	high	signal	for	ROS	production		(green)	overlapping	with	SYTO	61	signal.		Treatment	with	TCMDC-125529	(D)	showed	similar	signal	to	CQ,	while	TCMDC-124972	(E)	failed	to	produce	any	ROS	signal.		Line	signal	intensities	are	shown	along	the	bottom	and	right	of	each	image.		Scale	bars	represent	5	µm	for	each	image.			
Again,	we	sought	to	explain	the	different	compound	classes	observed	through	the	heme	speciation	assay	screening	results.		The	exemplary	compound,	TCMDC-125529,	exhibited	similar	high	signal	intensities	to	CQ-treated	cultures	at	the	IC50,	which	would	indicate	a	similar	interaction	with	parasitic	heme.		Contrarily,	TCMDC-124972	treatment	at	the	IC50	demonstrated	low	levels	of	ROS	present	within	the	parasite.		This	observation	may	provide	evidence	of	inhibition,	in	which	the	drug	prevents	hemozoin	formation	through	complete	complexation	of	heme.		This	would	decrease	ROS	production	by	toxic	heme,	allowing	for	increased	
	 A 	 B 
	 C 	D 	 E 
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accumulation	of	heme	prior	to	parasite	death,	as	was	observed	following	heme	fractionation.		Therefore,	this	particular	form	of	heme-drug	complex	can	shield	the	parasite	from	such	drastic	deleterious	effects,	increasing	the	time	required	for	parasitic	death	(Chapter	IV).		These	results	demonstrate	a	promising	method	for	understanding	the	various	types	of	hemozoin	inhibition;	however,	additional	compounds	must	be	tested	to	confirm	this	hypothesis.			
	 	 	
Conclusions	and	Future	Directions	
Initial	studies	with	fluorescently	labeled	CQ	have	begun	to	address	the	question	of	heme-drug	interaction.		Colocalization	with	nile	red	within	the	synthetic	NLDs,	supports	the	hypothesis	that	CQ	functions	through	capping	the	ends	of	the	growing	hemozoin	crystal,	as	crystal	growth	is	mediated	through	lipids.		However,	when	the	fluorescent	CQ	was	incubated	in	parasite	culture,	signal	was	observed	throughout	the	entire	cell.		This	result	correlates	with	the	proposed	mechanism	that	CQ	binds	to	heme	dimers	in	an	aqueous	environment	prior	to	the	incorporation	into	the	lipid	bodies	to	prevent	hemozoin	formation.	Inhibition	then	allows	for	the	accumulation	of	free	heme	in	the	parasite,	which	results	in	high	ROS	production,	as	observed	through	a	fluorescent	ROS	indicator.		This	was	contrasted	with	the	“high”	free	heme	accumulation	hemozoin	inhibitor,	TCMDC-124972,	that	showed	minimal	ROS	present	following	drug	treatment.		We	can	begin	to	deduce	why	there	are	differences	in	amounts	of	free	heme	through	these	types	of	fluorescent	experiments;	
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however,	ROS	probe	signal	must	first	be	quantified	using	flow	cytometry	before	definitive	conclusions	can	be	made.			
Furthermore,	resistance	to	common	antimalarials	has	become	more	prevalent	throughout	endemic	regions	due	to	mutations	or	changes	in	expression	levels	in	digestive	vacuole	membrane	proteins	such	as	PfCRT.49	This	protein	is	believed	to	reduce	drug	concentrations	in	the	digestive	vacuole	through	either	a	passive	or	active	process.51	Therefore,	with	strains	resistant	to	CQ,	we	expect	to	see	a	decrease	in	fluorescent	signal	inside	this	organelle	and	instead	localizing	in	the	cytosol.		
Exploring	the	mechanism	by	which	known	antimalarial	drugs	disrupt	biological	processes	within	Plasmodium	falciparum	can	improve	the	development	of	novel	compounds.		Screening	efforts	can	be	used	not	only	to	classify	libraries	of	compounds	by	mode	of	action,	but	also	to	validate	the	pathway	being	targeted	when	applied	in	culture.		Development	of	these	techniques	will	help	increase	the	drug	discovery	pipeline	for	new	antimalarials	with	greater	resilience	and	potency.		However,	if	malaria	is	to	be	eradicated	worldwide,	novel	drugs	that	target	all	three	stages	(hepatocyte,	erythrocyte,	and	gametocyte)	must	be	developed.		Recently,	high	throughput	screens	have	been	developed	for	gametocytocidal	activity.121,	122	If	these	complementary	screening	campaigns	are	compared,	the	results	will	dramatically	decrease	the	workload	and	efforts	can	be	combined	to	find	a	comprehensive	antimalarial.			
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Chapter	VI	
	
FINAL	THOUGHTS	
	
The	hemozoin	formation	pathway	is	an	extremely	unique	biological	drug	target	in	ways	that	should	not	be	overlooked	by	pharmaceutical	companies	when	developing	antimalarial	compounds.		To	begin	with,	this	target	pathway	is	only	found	among	blood	feeding	organisms,	each	known	to	transmit	human	diseases.		Additionally,	if	targeted	specifically	towards	hemozoin	formation,	these	parasitropic	drugs	should	have	limited	side	effects	for	the	human	hosts.	Since	over	95%	of	the	identified	drug	targets	consist	of	a	type	of	protein,	the	intrinsic	ability	to	gain	resistance	towards	small	molecules	is	extremely	common	by	genetic	alterations.123	However,	the	hemozoin	formation	pathway	is	impervious	to	developing	drug	resistance	through	a	genetic	mutation,	as	it	is	simply	a	biomineralization	process.	While	Plasmodium	species	are	resistant	to	certain	hemozoin	inhibitor	antimalarials,	such	as	CQ,	it	is	only	due	to	drug	efflux	mechanisms,	allowing	this	biocrystallization	process	to	still	be	an	effective	drug	target	pathway.	Therefore,	the	hemozoin	formation	pathway	is	one	of	the	most	ideal	drug	targets	for	antimalarial	compounds	and	should	be	the	first	priority	when	conducting	target-based	high	throughput	screens.			
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With	an	increase	of	resistance	to	nearly	all-current	antimalarial	treatments	there	is	a	great	need	for	novel,	inexpensive,	and	more	effective	compounds	to	be	developed.		In	our	attempts	to	provide	insight	to	the	malarial	drug	discovery	community,	we	utilized	a	model	systems	approach	(Figure	30).		First,	we	explored	the	lipophilic	template	required	for	hemozoin	formation	using	detergents	as	a	mimic,	which	provided	a	systematic	understanding	of	optimal	crystallization.		Through	discovering	the	importance	of	these	conditions	for	the	parasite,	researchers	can	target	this	biological	pathway	more	effectively.		We	then	used	these	ideal	conditions,	which	resemble	the	parasite	environment,	to	develop	a	HTS	assay	to	test	libraries	of	compounds	for	effective	β-hematin	inhibitors.		This	target-based	assay	was	used	as	the	initial	method	for	determining	hit	compounds.		To	confirm	the	results	and	purity,	dose	response	curves	were	generated	for	each	hit	compound,	which	resulted	in	a	numerical	potency	value.		The	most	active	compounds	were	then	screened	in	a	secondary	phenotypic	assay,	which	determined	P.	falciparum	viability,	again	in	a	dose	response	manner.		With	the	hits	from	the	primary	and	secondary	screens,	the	biological	target	of	hemozoin	formation	was	verified	in	a	parasite	culture.	This	target	validation	assay	eliminated	any	hit	compounds	that	inhibited	hemozoin	formation	secondarily	to	another	drug	target.		Through	these	assays,	the	vast	chemical	libraries	dwindled	down	to	a	small	set	of	highly	potent	compounds	with	a	validated	biological	target.		In	the	future,	structure-activity	relationship	studies	can	be	conducted	in	order	to	understand	the	activity	of	these	compounds	more	completely.	This	results	in	a	deeper	knowledge	of	the	structural	characteristics	that	are	vital	for	potency	and	can	help	tailor	the	compounds	to	be	
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structurally	most	effective	for	patients	as	well	as	for	pharmaceutical	companies	during	the	manufacturing	process.		Furthermore,	compounds	can	be	tested	for	absorption,	distribution,	metabolism,	and	excretion	characteristics	for	pharmacological	analyses	of	drug-likeness.		Finally,	both	in	vitro	and	in	vivo	toxicity	studies	must	also	be	conducted	prior	to	any	compound	reaching	clinical	testing.			
Along	with	other	collaborators	and	lab	members,	a	select	number	of	compounds	have	traveled	through	this	workflow	in	hopes	of	developing	a	novel	and	more	effective	hemozoin	inhibitor	antimalarial.		This	work	will	continue	at	the	University	of	Cape	Town	in	South	Africa	working	towards	finding	a	particularly	
Systema-c	study	of	detergents	as	lipophilic	mimics	
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Figure	30	The	general	workflow	for	the	target-based	drug	discovery	process	to	find	an	effective	hemozoin	inhibitor	antimalarial	compound.		
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potent	scaffold.		Through	the	synthesis	of	similar	compounds,	structural	efficacy	as	well	as	purity	can	be	confirmed.		Collaborators	at	Stellenbosch	University	are	continuing	the	work	on	understanding	of	how	compounds	interact	with	the	growing	crystal	or	the	heme	dimer,	again	to	design	an	ideal	hemozoin	inhibitor.			The	most	potent	antimalarial	compounds	that	inhibit	hemozoin	formation	can	then	be	sent	to	additional	laboratories	to	conduct	the	in	vivo	toxicity	studies.			
The	Medicines	for	Malaria	Venture	has	several	new	initiatives	to	help	spawn	research	on	this	disease	and	has	made	open	collaboration	easier	through	releasing	the	screening	results	from	GlaxoSmithKline,	Novartis,	and	St	Jude	Children’s	Research	Hospital	to	the	public.	Using	the	information	from	these	screens,	research	groups,	like	ours,	have	been	able	to	focus	on	target	pathway	validation	of	the	hit	compounds	in	hopes	of	finding	antimalarial	compounds	with	known	targets	that	are	potent	against	both	drug	sensitive	and	resistant	strains	of	P.	falciparum.		Through	the	investigations	of	how	antimalarial	compounds	interact	with	the	hemozoin	formation	pathway,	we	provided	insight	into	how	these	drugs	interrupt	this	biological	process.	We	are	currently	looking	to	identify	key	components	of	the	molecular	structure,	which	facilitate	hemozoin	inhibition	in	order	to	prioritize	hit	compounds.		Furthermore,	we	seek	to	understand	the	role	of	heme-drug	complexes	in	producing	lethal	effects	against	the	malaria	parasite.		Through	the	collaboration	of	the	entire	malaria	community	there	is	great	hope	for	a	radical	cure	for	malaria,	described	by	Paul	Ehrlich	as	therapia	sterilisans	magna,	a	large	dose	single	treatment	used	to	destroy	the	entire	parasitic	agent	without	doing	harm	to	the	host	patient.124		
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Appendix	B	
	
Malaria	SYBR	Green-I	Fluorescence	Assay2	
	 The	Malaria	SYBR	Green-I	Fluorescence	(MSF)	assay	was	modified	from	a	previously	published	method125	and	used	to	determine	drug	susceptibility	against	P.	
falciparum.	Compounds	were	dissolved	in	DMSO	at	a	concentration	of	10	mM	and	transferred	to	384-well	optical	bottom	black	microtiter	plates	using	an	ECHO	555	liquid	handler	in	the	Vanderbilt	High-Throughput	Screening	Core	Facility.	Initial	screening	was	done	with	final	compound	concentrations	of	23	μM	in	duplicate.		To	determine	IC50	values	of	the	hit	compounds,	dose	response	curves	were	established	by	testing	compound	concentrations	from	0.03-23	μM	with	a	final	DMSO	concentration	of	0.25%.		To	ensure	that	DMSO	did	not	interfere	with	parasite	growth,	control	wells	containing	0.25%	DMSO	and	no	DMSO	were	included.		A	synchronized	culture	of	ring	stage	parasites	was	added	to	the	compounds	at	0.3%	initial	parasitemia	and	2%	hematocrit.		Following	a	72-hour	incubation,	the	parasites	were	lysed	with	10	mM	EDTA,	100	mM	Tris-HCl	(pH	7.5),	0.16%	(w/v)	saponin,	and	1.6%	(v/v)	Triton	X-100.	SYBR	Green-I	(1:10,000	dilution)	was	added	to	the	assay	plate	without	mixing	and	allowed	to	incubate	for	24	hours	before	reading	the	fluorescence	at	485	nm	and	535	nm	excitation	and	emission	wavelengths,	respectively.	Concentration	response	curves	were	generated	using	GraphPad	Prism	v5.0	with	duplicate	sample	wells	for	each	compound	(Figure	31).		
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Figure	31	Workflow	of	the	Malaria	SYBR	Green-I	Fluorescence	based	assay.		
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Appendix	C	
	
Full	Screening	Results	of	Top	225	GSK	Hit	Compounds	
	 The	following	pages	include	the	top	225	hit	compounds	from	the	GlaxoSmithKline	library	screen,	which	exhibited	>90%	β-hematin	inhibition.		The	table	is	listed	in	order	of	the	TCAMS	identifier	numbers	and	includes	the	percent	inhibition	from	the	initial	screen,	the	mean	and	standard	deviation	for	the	IC50	values	measured	from	two	replicates	(µM),	the	reported79	3D7	IC50	antiplasmodial	activity	(µM),	and	the	structure	of	each	compound.			
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-123466 99 16.7 1.5 0.277
TCMDC-123486 95 13.7 3.4 0.512
TCMDC-123506 96 375.8 NC 0.134
TCMDC-123601 91 27.5 8.8 0.890
TCMDC-123680 100 16.7 0.01 0.267
TCMDC-123692 100 17.5 1.5 0.814
TCMDC-124127 94 15.3 1.3 1.117
TCMDC-124421 100 16.6 0.6 0.718
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-124423 100 14.3 1.3 0.378
TCMDC-124526 99 15.2 1.2 1.588
TCMDC-124822 91 16.8 1.8 0.874
TCMDC-124969 99 25.1 3.0 0.647
TCMDC-124972 97 14.5 2.8 1.054
TCMDC-125220 94 12.1 2.5 0.799
TCMDC-125274 100 9.7 0.5 1.090
TCMDC-125364 100 46.6 4.2 0.646
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-125415 95 19.3 1.2 0.258
TCMDC-125505 99 8.9 0.3 0.774
TCMDC-125529 99 12.9 2.4 0.830
TCMDC-125530 100 8.4 1.0 0.659
TCMDC-125577 98 27.7 4.4 0.524
TCMDC-125600 95 16.0 0.9 0.168
TCMDC-125671 100 7.8 1.9 0.614
TCMDC-125788 100 18.4 3.0 0.761
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-131238 100 62.1 4.4 0.927
TCMDC-132028 95 38.5 1.6 0.167
TCMDC-132120 92 29.1 8.3 1.244
TCMDC-132130 101 15.7 0.1 0.161
TCMDC-132131 97 9.9 0.9 0.889
TCMDC-132135 100 13.7 0.4 0.633
TCMDC-132141 99 12.4 0.3 0.789
TCMDC-132143 94 15.3 2.0 1.743
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132144 92 17.6 1.2 0.767
TCMDC-132145 98 14.7 1.3 0.452
TCMDC-132159 100 14.4 0.4 0.302
TCMDC-132160 96 20.6 2.6 0.557
TCMDC-132167 100 13.8 0.7 0.313
TCMDC-132178 102 16.5 0.03 0.793
TCMDC-132189 98 16.2 1.0 0.829
TCMDC-132192 99 15.4 0.5 0.323
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132201 100 11.2 1.3 0.410
TCMDC-132320 98 21.6 0.6 0.519
TCMDC-132405 98 11.1 2.8 0.119
TCMDC-132419 100 26.2 3.9 0.090
TCMDC-132558 100 14.2 0.8 0.194
TCMDC-132566 98 15.6 0.6 0.255
TCMDC-132571 100 16.1 1.4 0.396
TCMDC-132695 90 48.0 7.1 0.907
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132710 100 16.9 0.1 0.148
TCMDC-132729 99 16.4 2.2 0.130
TCMDC-132821 91 34.0 2.1 0.607
TCMDC-132829 97 36.7 13.0 0.772
TCMDC-132840 90 26.6 13.0 0.670
TCMDC-132845 94 12.2 0.2 0.099
TCMDC-132846 100 15.4 0.7 0.119
TCMDC-132849 95 23.1 5.8 0.117
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132854 92 18.6 1.6 0.115
TCMDC-132857 92 50.5 3.7 0.170
TCMDC-132862 100 25.5 11.8 0.910
TCMDC-132897 96 14.8 1.1 0.138
TCMDC-132898 98 18.4 3.4 0.184
TCMDC-132906 94 16.5 1.2 0.156
TCMDC-132910 99 23.2 3.5 0.200
TCMDC-132915 97 16.2 0.4 0.062
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-132947 92 20.0 0.8 0.156
TCMDC-132958 93 15.1 1.5 0.157
TCMDC-133009 98 41.6 2.2 0.308
TCMDC-133042 95 16.3 1.4 0.146
TCMDC-133044 94 17.1 0.9 0.140
TCMDC-133052 91 14.6 0.04 0.215
TCMDC-133135 93 14.8 0.1 0.277
TCMDC-133136 92 17.6 0.5 0.170
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-133155 91 12.8 0.5 0.715
TCMDC-133158 90 16.2 2.1 0.231
TCMDC-133171 99 25.5 3.9 0.756
TCMDC-133177 90 14.5 1.8 0.199
TCMDC-133194 98 21.6 2.1 0.104
TCMDC-133210 92 29.7 0.4 0.351
TCMDC-133257 99 22.9 2.0 0.630
TCMDC-133460 94 65.6 0.8 0.978
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-133550 94 18.9 2.2 0.837
TCMDC-133699 97 14.7 1.1 0.738
TCMDC-133701 98 18.4 2.6 0.240
TCMDC-133702 99 25.4 4.5 0.534
TCMDC-133705 94 28.8 7.1 0.572
TCMDC-133932 98 26.8 3.4 0.142
TCMDC-133935 96 39.1 1.5 0.147
TCMDC-133940 96 36.3 4.1 0.142
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-133941 100 17.3 0.6 0.153
TCMDC-134151 95 15.6 1.7 0.149
TCMDC-134493 100 41.6 3.7 0.860
TCMDC-135054 99 14.0 0.8 0.930
TCMDC-135247 92 NC NC 0.698
TCMDC-135248 91 15.6 2.5 0.570
TCMDC-135250 99 15.8 0.7 0.975
TCMDC-135305 97 306.5 NC 0.213
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-135360 92 35.6 5.1 0.906
TCMDC-135405 100 14.3 1.1 0.138
TCMDC-135406 93 11.9 3.6 0.111
TCMDC-135456 97 49.3 2.7 0.832
TCMDC-135478 94 16.2 0.01 0.197
TCMDC-135507 99 14.9 1.9 0.174
TCMDC-135542 91 16.0 5.5 0.109
TCMDC-135557 95 14.3 0.9 0.279
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-135688 100 24.0 0.1 0.832
TCMDC-135912 92 20.2 3.8 0.754
TCMDC-135945 100 27.6 5.3 0.840
TCMDC-136145 99 18.6 1.5 0.804
TCMDC-136152 100 19.1 5.9 0.828
TCMDC-136194 99 13.7 0.2 1.510
TCMDC-136243 100 16.1 0.3 0.888
TCMDC-136287 100 7.0 1.4 0.122
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136818 95 18.9 5.3 0.990
TCMDC-136819 90 23.8 8.8 0.238
TCMDC-136820 96 15.4 4.2 0.204
TCMDC-136824 92 12.6 1.2 0.134
TCMDC-136830 99 9.7 2.4 0.065
TCMDC-136831 101 9.0 1.5 0.265
TCMDC-136837 98 14.6 1.3 0.726
TCMDC-136853 100 33.7 11.1 1.087
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136859 99 14.8 0.5 0.585
TCMDC-136862 100 16.7 0.7 0.733
TCMDC-136906 97 14.9 1.2 1.088
TCMDC-136913 94 15.1 1.0 0.643
TCMDC-136914 92 14.3 5.5 0.454
TCMDC-136922 96 19.3 1.9 0.363
TCMDC-136923 99 21.1 6.4 0.612
TCMDC-136927 91 15.6 2.1 0.228
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136940 95 51.6 10.3 1.025
TCMDC-136941 91 36.0 20.6 0.797
TCMDC-136946 92 35.0 8.3 0.806
TCMDC-136951 97 14.2 1.2 0.688
TCMDC-136954 92 25.8 10.2 0.789
TCMDC-136957 90 15.4 2.7 0.719
TCMDC-136960 90 19.7 3.6 0.681
TCMDC-136961 92 15.0 0.9 0.278
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-136965 100 35.3 14.2 0.236
TCMDC-136966 101 11.6 1.8 0.497
TCMDC-136970 93 18.0 3.2 1.045
TCMDC-136992 97 21.2 0.1 0.635
TCMDC-136993 101 14.1 1.1 0.627
TCMDC-136998 99 11.2 2.5 0.596
TCMDC-137034 98 10.6 0.03 0.857
TCMDC-137037 91 17.0 2.7 0.581
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137059 100 24.1 4.4 0.735
TCMDC-137063 100 15.7 2.4 0.167
TCMDC-137065 92 34.1 5.8 0.560
TCMDC-137067 91 19.1 4.1 0.670
TCMDC-137068 93 25.8 0.2 0.645
TCMDC-137072 100 7.1 1.0 0.651
TCMDC-137087 101 12.8 2.4 0.630
TCMDC-137092 100 21.8 1.4 0.958
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137094 98 10.1 2.6 0.289
TCMDC-137110 90 48.4 0.5 0.413
TCMDC-137120 99 11.5 3.0 0.552
TCMDC-137125 97 15.8 0.3 0.182
TCMDC-137129 98 9.8 2.5 0.185
TCMDC-137131 95 9.2 1.0 0.232
TCMDC-137135 97 32.3 9.4 0.715
TCMDC-137136 92 23.5 3.2 0.388
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137137 99 15.5 0.9 0.505
TCMDC-137180 99 16.8 2.8 1.477
TCMDC-137212 100 17.0 3.4 0.035
TCMDC-137480 98 117.9 NC 0.104
TCMDC-137481 100 14.9 0.5 0.152
TCMDC-137582 98 15.6 0.3 0.104
TCMDC-137793 91 84.7 16.6 0.143
TCMDC-137869 100 14.5 0.7 0.168
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-137902 96 55.6 12.4 0.376
TCMDC-137983 100 43.1 0.6 0.395
TCMDC-138197 100 20.8 7.3 0.174
TCMDC-138205 98 9.8 2.4 0.111
TCMDC-138256 94 20.1 5.0 0.445
TCMDC-138432 100 50.0 50.6 0.237
TCMDC-138451 99 34.5 22.0 0.186
TCMDC-138467 93 13.2 1.9 0.557
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-138486 100 16.2 1.4 0.132
TCMDC-138520 100 15.5 1.8 0.335
TCMDC-138557 99 47.4 3.0 0.776
TCMDC-138659 93 15.0 4.1 0.915
TCMDC-138660 94 10.3 0.2 0.608
TCMDC-138686 98 47.1 0.5 0.818
TCMDC-138696 99 12.2 0.4 0.716
TCMDC-138752 100 11.7 4.5 0.278
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-138898 100 44.6 1.3 0.925
TCMDC-138911 100 25.6 0.9 0.751
TCMDC-139008 99 57.1 4.4 1.161
TCMDC-139205 100 NC NC 0.530
TCMDC-139268 98 37.3 4.8 0.158
TCMDC-139383 93 20.5 2.9 0.573
TCMDC-139406 92 23.8 10.4 0.695
TCMDC-139410 97 12.5 2.9 0.256
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-139498 100 17.5 0.6 0.314
TCMDC-139502 99 25.3 3.8 0.063
TCMDC-139550 100 22.4 1.0 0.114
TCMDC-139559 98 9.0 2.7 1.006
TCMDC-139871 96 42.0 4.4 0.776
TCMDC-140218 93 15.2 0.7 0.911
TCMDC-140319 100 22.4 8.0 1.168
TCMDC-140344 100 34.4 2.3 0.514
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-140347 100 21.4 1.6 0.894
TCMDC-140367 95 20.1 0.9 0.734
TCMDC-140540 91 14.3 1.2 0.684
TCMDC-140648 90 16.4 2.7 1.120
TCMDC-140681 98 14.6 0.7 0.464
TCMDC-140797 98 15.7 2.5 0.895
TCMDC-140827 92 30.5 4.6 0.759
TCMDC-141000 99 12.6 1.9 0.135
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-141338 100 15.0 1.6 0.978
TCMDC-141388 100 13.5 0.1 0.121
TCMDC-141392 95 15.7 3.2 0.617
TCMDC-141399 97 20.4 2.6 0.762
TCMDC-141560 100 12.3 2.1 0.801
TCMDC-141561 93 15.2 0.2 1.018
TCMDC-141584 93 19.8 1.3 0.344
TCMDC-141585 100 44.0 2.6 0.531
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-141609 100 13.9 0.3 0.272
TCMDC-141610 97 14.7 1.4 0.287
TCMDC-141611 99 13.1 1.6 0.859
TCMDC-141612 100 16.3 0.8 0.736
TCMDC-141978 96 11.2 2.4 0.983
TCMDC-142040 100 13.3 0.1 0.202
TCMDC-142048 94 9.1 0.5 0.030
TCMDC-142308 100 12.8 0.7 0.873
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Identifier %βH	Inhibition Avg	βH	IC50	(µM) StDev 3D7	IC50	(µM) Structure
TCMDC-142335 94 49.9 0.3 0.253
